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Abstract 
A series of eleven different nickel Schiff base complexes was synthesized by 
a two-step procedure. Initially ethylenediamine, phenylenediamine or meso-
1,2-diphenylethylenediamine was reacted with either 2,3- or 2,5-
dihydroxybenzaldehyde in the presence of Ni(II) to afford six novel 
dihydroxylated nickel Schiff base complexes. Five of these complexes were 
then successfully reacted with 1-(2-chloroethyl) piperidine hydrochloride to 
form a series of derivatives featuring two appended ethyl piperidine moieties. 
All new complexes were characterised using 1D and 2D nuclear magnetic 
resonance (NMR) spectroscopy, elemental microanalysis and in some 
instances electrospray ionisation mass spectrometry (ESI-MS). The solid-
state structures of three nickel complexes (5), (8) and (10) were determined 
by single crystal X-ray crystallography, and revealed that the coordination 
geometry around the nickel ion was square planar in each case.  
The ability of the nickel complexes containing appended ethyl piperidine 
groups to bind to a double-stranded 16mer DNA molecule, and a 
tetramolecular DNA quadruplex, was investigated using ESI-MS and circular 
dichroism (CD) spectroscopy. The results of these studies, as well as those 
performed simultaneously using a series of previously reported analogues 
prepared by the same synthetic pathway, but with 2,4-
dihydroxybenzaldehyde as one of the initial reactants, enabled the effect of 
varying the position of the ethyl piperidine groups on DNA-binding properties 
to be explored. Generally, it was found that changing the position of the ethyl 
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piperidine groups had only a small effect on binding affinity towards either 
type of DNA molecule. In most cases there was good agreement between 
orders of relative binding affinity towards a given DNA molecule determined 
using the two spectroscopic techniques. On some occasions, however, the 
results of binding studies conducted using ESI-MS and CD spectroscopy 
diverged significantly. This may have been the result of the two methods 
showing different sensitivities towards different aspects of the metal 
complex/DNA interaction, and the varying stabilities of the non-covalent 
complexes formed in these systems, to the gas phase environment of the 
ESI mass spectrometer or to the solution phase used in CD experiments. 
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CHAPTER 1 INTRODUCTION 
1.1 Historical overview of anticancer drugs 
Over the years, several treatment options for cancer have been developed. 
These comprise surgery, radiotherapy and chemotherapy, as well as 
combinations of all three approaches. Cancer treatment based on surgery or 
radiotherapy cures only about half of the cancer cases, and then may only 
prolong the lives of patients. The aim of most chemotherapeutic treatments is 
to kill tumour cells through inhibition of cell division. Accordingly, many 
cytotoxic anticancer drugs have been developed through this approach. 
Deoxyribonucleic acid (DNA) is well known as the intracellular target for a 
wide range of compounds which exhibit antibacterial, antiviral and anticancer 
properties.1 The interaction of anticancer drugs with DNA molecules, 
enzymes and also some proteins may cause inhibition of cellular division 
mechanisms, eventually leading to cancer cell death. Cytotoxic agents can 
damage DNA either directly or indirectly. Direct damage is caused through 
disruption of DNA replication, while indirect damage is caused through 
inhibiting the synthesis of the building blocks of DNA, such as folic acid, the 
four heterocyclic bases, or the corresponding nucleotides. Nitrogen mustards 
are examples of anticancer drugs that damage DNA directly, while folic acid 
analogues are examples of anticancer drugs that damage DNA indirectly.2-6 
During the last few decades numerous compounds with anticancer activity 
have been investigated, however many of them cannot be used clinically due 
to their toxic side effects and lack of specificity. In order to be potentially 
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useful as an anticancer agent, a chemical compound must exhibit a high 
degree of selective cytotoxicity towards cancer cells, as well as produce few 
side effects when administered to patients. 
Initially, the discovery of most anticancer drugs was based on the 
experimental observation of the biological effects of large numbers of 
chemical compounds or serendipitous discoveries, rather than knowledge of 
their mechanisms of biological action. Despite this, some chemical 
compounds have been successful in curing or prolonging the survival of 
many cancer patients.7 Nitrogen mustard derivatives, folic acid analogues 
and platinum complexes are just some examples of a wide range of chemical 
compounds that have been used successfully as anticancer drugs in recent 
decades, and continue to be used in the clinic. 
The anticancer activity of the mustards was first discovered in 1935, when 
the ability of mustard gas to inhibit the transplantation of tumours in animal 
models was reported.8 This anticancer activity attracted more attention when 
soldiers died as a result of their exposure to sulfur mustard during the 
Second World War. It was observed that sulfur mustard caused massive 
damage to bone marrow and lymph nodes in gas-exposed persons.9-11 The 
toxic effect on the lymphatic system suggested a possible use of mustards as 
anticancer drugs for treatment of lymphomas and leukaemias. Although 
sulfur mustard was highly toxic when used in cancer therapy, it led to the 
development of a series of analogues known as the nitrogen mustards. In the 
early 1940s, Goodman and Gilman examined the potential therapeutic 
effects of nitrogen mustard (mechlorethamine, Figure 1.1a) on a transplanted 
3 
 
lymphoid tumour. After using it in clinical trials on patients with non–
Hodgkin’s lymphoma and severe airway obstruction, marked regression was 
observed.9,12,13 Unfortunately, treatment with mechlorethamine resulted in 
severe side effects. This led to the development of chlorambucil and 
melphalan (Figure 1.1b and c, respectively) which are widely used for the 
treatment of lymphoma, leukaemia and ovarian carcinoma.14 
 
Figure 1.1: The structure of nitrogen mustard and some derivatives; a) 
nitrogen mustard (mechlorethamine); b) chlorambucil, and c) melphalan. 
 
Nitrogen mustards were used as anticancer agents long before their 
mechanism of action was understood. It has since been found that they 
induce cell death by preventing the normal sequence of DNA replication, 
through interstrand cross-linking of DNA.2-4 DNA was not identified as the 
target of the mustards until after Watson and Crick proposed their model for 
the structure of DNA in 1953.15,16 Cross-linking the two DNA strands blocks 
DNA replication by preventing strand separation, as well as bending the 
DNA, leading eventually to cell death.3,17 
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After the discovery of the effect of folate deficiency on bone narrow, a series 
of folic acid analogues including aminopterin and methotrexate were 
developed (Figure 1.2). Later, these folate antagonists were administered to 
children with leukaemia, and it was found that they can induce remission.18,19 
Methotrexate was also used successfully to treat metastatic cancer in 1956.20 
Aminopterin and methotrexate were used as chemotherapeutic agents long 
before their mechanism of action was reported by Osborn et al. in 1958.5,6 
Both are antimetabolites that act through inhibiting dihydrofolate reductase, a 
folate-requiring enzyme needed for DNA replication. This results in 
interference with folate synthesis, eventually leading to cell death.5,6 
 
 
Figure 1.2: Structure of some folic acid analougues used clinically as 




Over the years, many other anticancer drugs which inhibit cell growth and/or 
affect the integrity of DNA have been developed. The ongoing design and 
synthesis of metal-based anticancer drugs stems from the serendipitous 
discovery of the anticancer properties of cisplatin (cis-
(diamminodichloro)platinum(II)) (Figure 1.3a) by Rosenberg et al.21-23 
Cisplatin binds covalently to DNA predominantly via intrastrand cross-links 
with the purine bases adenine and guanine. This process involves the two 
chlorine atoms of cisplatin being replaced by the N7 atoms of two adjacent 
purines on the same DNA strand.24-27 
 
 
Figure 1.3: Structure of some platinum anticancer complexes: a) cisplatin; b) 
carboplatin, and c) oxaliplatin. 
 
The binding of cisplatin to DNA results in bending and unwinding of the 
double helix, ultimately leading to the cell undergoing apoptosis.28-33 Cisplatin 
is highly cytotoxic towards a variety of tumours such as testicular, ovarian, 
head and neck, and bladder carcinomas, as well as lymphoma.34-41 
Unfortunately, cisplatin does not exert its cytotoxicity selectively towards 
cancer cells, resulting in severe side effects including nausea, ear damage, 
vomiting, nephrotoxicity, neurotoxicity, and emetogenesis.42-44 As a result of 
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attempts to overcome these toxic side effects, a number of less toxic 
platinum drugs have been developed. These include carboplatin (Figure 
1.3b), which is effective for the treatment of ovarian cancer, and oxaliplatin 
(Figure 1.3c), which is used to treat colon cancer. 
Increased understanding of cancer biology, developments in molecular 
biology techniques, and elucidation of the complete sequence of the human 
genome have all led to the development of new therapeutic approaches 
known as targeted therapies.45 Targeted therapies are based on designing 
drugs that interfere with the activity of a specific biological target or process 
which is critical for cancer cell survival, such as a gene, enzyme or protein.45 
In the recent years, many drug targets have been identified for targeted 
therapy approaches, including DNA polymerases and topoisomerases, 
kinase signalling pathways, nuclear hormone receptors in breast and 
prostate cancer, and telomerase. Since the therapeutic activity of many 
anticancer drugs is a result of their binding to DNA, understanding the 
structure and mechanism of replication of nucleic acids has played a 
significant role in the development of targeted therapy. 
 
1.2 Duplex DNA 
DNA, or deoxyribonucleic acid, is a hereditary material that is present in the 
vast majority of living organisms. DNA is the main constituent of 
chromosomes, and its genetic information is used to synthesise the proteins 
that are required for numerous biological functions and processes.46,47 
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DNA is a polymer made from repeating units called deoxyribonucleotides that 
link together through phosphodiester bonds. Each deoxyribonucleotide is 
composed of deoxyribose sugar, a phosphate group, and a nitrogenous 
base, which could be either a pyrimidine (cytosine (C) or thymine (T)), or a 
purine (adenine (A) or guanine (G)) (Figure 1.4).48 The nitrogenous base is 
linked to deoxyribose forming a nucleoside. The nucleosides are joined 
together by phosphate groups that form phosphodiester bonds with the 5-
hydroxyl group on one nucleoside and the 3-hydroxyl group on the 
neighbouring nucleoside. This linkage results in the formation of a single 
DNA strand. 
 
Figure 1.4: The chemical structures of the nitrogenous bases present in 
DNA. 
 
B-DNA is the most common form of double-stranded DNA (dsDNA) that is 
found in biological systems, and its structure was first determined by Watson 
and Crick in 1953.15 By using results obtained from X-ray diffraction, they 
determined that this form of DNA is an anti-parallel, right-handed double 
helical molecule, with the two polynucleotide chains held together by 
hydrogen bonds between the pyrimidine and purine bases on opposite 
strands (base pairing) (Figure 1.5a).15 Base pairing occurs when adenine 
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residues on one strand form two hydrogen bonds with thymine residues on 
the opposite strand, and guanine residues form three hydrogen bonds with 
cytosine residues (Figure 1.5b). In addition to base pairing, interactions 
between the π electron clouds of the bases contribute to the overall stability 
of B-DNA.  
 
Figure 1.5: a) Schematic illustration of the structure of double-stranded DNA. 
b) Structures of the two types of Watson-Crick base pairs present in B-form 
DNA. 
 
There are two less common forms of duplex DNA, known as A- and Z-DNA 
(Figure 1.6). In low humidity environments B-DNA can convert to A-DNA, 
which also has a right handed helical structure.49 Duplex DNA can also adopt 
the Z-form structure in solutions with high salt concentrations.50,51 Z-DNA is a 




Figure 1.6: The structures of A-DNA, B-DNA and Z-DNA. Adapted from 
various references.53,54  
 
It has been discovered that some proteins bind to Z-DNA with high affinity 
and specificity, and that B-DNA can change to Z-DNA in the hippocampus of 
brains of patients with Alzheimer’s disease.55 These findings suggest that the 
Z-DNA conformation may play a biological role in a variety of cellular 
functions. 
As a result of the geometrical configuration of the bonds between the 
deoxyribose sugar-phosphate backbone and the nitrogenous bases in the B-
DNA structure, two different sized grooves, the major and minor grooves, 
form along the surface of the nucleic acid.46,56 A wide range of proteins, 
oligonucleotides and metal complexes can bind to DNA through these 
grooves.57 Since the major and minor grooves vary in their hydrogen bonding 
characteristics, electrostatic potential, extent of hydration and size and 
shape, it has been found that some molecules prefer to bind in one groove 
A-DNA B-DNA Z-DNA 
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over the other. For instance, it was observed that small organic molecules 
with a crescent shape act as minor groove binders, while proteins and 
oligonucleotides act as major groove binders.58 The interactions between 
DNA and groove binding molecules include van der Waals, electrostatic and 
hydrophobic interactions, as well as hydrogen bonding with the DNA base 
pairs.59-62 
The naturally occurring antibiotics distamysin and netropsin (Figure 1.7) are 
examples of dsDNA minor groove binders.60 It has been found that these 
molecules prefer to interact with AT-rich DNA sequences. This binding 
preference is attributed to the fact that AT-rich regions are less sterically 
demanding, and able to participate in strong electrostatic binding 
interactions.61 On the other hand, the interaction of minor groove binders with 
GC-rich dsDNA sequences is inhibited for steric reasons, owing to the 
formation of hydrogen bonds between the amino group of the guanines and 




Figure 1.7: Structure of some DNA minor groove binders: a) distamycin, and 
b) netropsin. 
 
The structure of double helical DNA also offers an additional binding site to 
the minor and major grooves. Some small aromatic molecules can insert 
themselves and stack between adjacent base pairs within the DNA double 
helix.59 Such molecules are known as intercalators. Intercalative binding is 
stabilized by hydrogen bonding, charge transfer and hydrophobic interactions 
between the aromatic intercalator and the DNA base stack.63 The 
interactions between the π-orbitals of the intercalating ligand and those of the 
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base pairs widen the gaps between the base pairs, resulting in unwinding 
and bending of the DNA molecule, and an increase in its length.47,56,64 
The DNA stain ethidium bromide (EtBr) and the anticancer drug daunomycin 
(Figure 1.8) are examples of organic intercalators.47,65 The binding of 
daunomycin is further stabilized by the formation of hydrogen bonds between 
the hydroxyl group of the daunomycin glycone ring and an adjacent guanine 
base. These hydrogen bonds were found to play a significant role in the 
biological activity of daunomycin.65 Many intercalators have also been found 
to possess a positive charge, which facilitates electrostatic binding 
interactions with dsDNA.66,67 
 
Figure 1.8: Structure of some organic intercalators: a) ethidium bromide, and 
b) daunomycin. 
 
1.3 Quadruplex DNA and telomeres 
In addition to the double helical structures, certain DNA sequences can form 
multistranded helices such as  quadruplexes (G-tetraplexes), and i-motifs (i-
tetraplexes) which have been identified by some crystallographic and NMR 
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studies.68-72 In particular, G-quadruplex DNA has attracted considerable 
interest in recent years because of its ability to form in telomeric DNA 
sequence, and also act as an inhibitor for telomerase, the enzyme 
responsible for telomere maintenance.73-75 
Telomeres are found at the ends of linear eukaryotic chromosomes, and are 
comprised of telomeric DNA bound to a variety of proteins. Telomeric DNA is 
composed of tandem repeats of noncoding double-stranded base 
sequences, and with a guanine-rich strand forming a protruding 3 single-
strand overhang.69 For instance, repeats of the sequence d(TTAGGG)  
constitute human telomeres, while repeats of the sequence d(TTTTGGGG) 
are found in the telomeres of the protozoa Oxytricha novat.69,76 
Telomeres play a vital role in cell growth and proliferation, as they protect 
chromosomes from degradation and fusion with each other.69 Their role is to 
maintain the structural integrity of chromosomes by protecting their ends from 
being recognized as double-strand breaks during cell division.77,78 Normal 
somatic cells progressively lose telomeric repeats during cellular division, 
with the chromosomes shortening by 50–200 bases after each round of DNA 
replication.77 Losing telomeric DNA means that important genetic information 
is not lost with each round of cellular division. However, when the length of 
telomeric DNA decreases to a critical length, dsDNA cannot replicate 
anymore, and the cell enters a senescent state, after which it undergoes 
apoptosis, and dies.77 This process can be prevented by telomerase, a 
ribonucleoprotein enzyme made of protein and RNA subunits. Its biological 
role is to maintain telomere length by adding G-rich DNA repeat sequences 
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onto the 3′-end of telomeric DNA.77,79 Telomerase activity is typically tightly 
regulated during development, and exhibits minimal activity in somatic cells, 
which leads to a gradual shortening of telomeres as the organism ages.  
In contrast, telomerase has been found to be much more active in germ cells 
and human tumours.77 Stabilization of telomere lengths by telomerase 
contributes to more than 90% of human cancer cells effectively exhibiting 
cellular immortality.80,81 
In vivo, it has been shown that the single-stranded G-rich overhangs of 
telomeres are susceptible to folding into a variety of guanine-rich DNA 
structures known as G-quadruplexes.78,82 This telomeric quadruplex DNA has 
attracted widespread interest as a therapeutic target for cancer treatment.83 
G-quadruplexes are made from G-rich DNA sequences arranged to form 
multiple stacked guanine tetrads held together by π-stacking interactions and 
stabilized by monovalent cations (such as potassium or sodium) that are 
located between each pair of G-tetrads (Figure 1.9a).69,84 A G-tetrad is a 
square planar array of four guanine bases held together by eight Hoogsteen 
hydrogen bonds (Figure 1.9b).78,69 
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Figure 1.9: a) a schematic structure of a G-quadruplex formed by stacking of 
G-tetrads from four parallel DNA strands; b) structure of a G-tetrad featuring 
the Hoogsteen hydrogen bonding. (M+ = Na+ or K+).  
 
G-Quadruplex DNA exhibits a variety of three dimensional structures that are 
formed through either folding of a single DNA strand (intramolecular folding), 
or the association of two or four strands of DNA (intermolecular 
association).The structural diversity of G-quadruplexes is due in part to the 
range of strand orientations (parallel, antiparallel or hybrid) observed (Figure 
1.10). These different topologies depend on a wide variety of factors, such as 
loop length, DNA strand sequence, number of individual G-tetrads, and the 
surrounding environmental conditions.84-88 The different topologies of G-
quadruplex DNA provide access to a variety of chemical functional groups 




Figure 1.10: Schematic illustration of some different qDNA topologies: a) 
Intermolecular parallel tetramolecular G-quadruplex; b) intermolecular 
antiparallel bimolecular G-quadruplex; c) intramolecular antiparallel 
unimolecular G-quadruplex. Adapted from various references.89,90 
 
In addition to their occurrence in telomeric regions, guanine-rich DNA 
sequences that are susceptible to adopting G-quadruplex DNA structures are 
found in other locations in the human genome, including chromosomes, 
centromeres, fragile X syndrome repeats, the c-myc gene, retinoblastoma 
susceptibility genes, and human insulin genes.89,91-93 This indicates that G-
quadruplex structures may also have a role in other diseases besides cancer. 
The formation of G-quadruplexes in these regions also means they may be 
involved in various biological functions such as regulation of transcription and 
translation, DNA recombination, and replication of DNA stands.68,94-99 
However, during the last few years the majority of research has focused on 














Inhibition of telomerase activity in cancer cells has attracted attention as a 
new approach to cancer treatment. It has been shown that the folding of 
telomeric DNA into G-quadruplex structures impedes telomerase from 
elongating telomeres.82 Some studies in cancer cells have shown that small 
molecules which bind to and stabilize G-quadruplexes have caused damage 
to the telomeres as a result of their dissociation from single-stranded DNA 
(ssDNA) templates.40,73-75,82,103,104 It has been shown that such molecules 
bind to quadruplex DNA either by intercalation between the G-tetrads or 
through stacking with terminal G-tetrads.105 A wide range of qDNA-binding, 
small aromatic molecules have been investigated. These include 
anthraquinones (e.g. 2,6-diamidoanthraquinone), acridines (e.g. BRACO19= 
N-[9-[4-(dimethylamino)anilino]-6-(3-pyrrolidin-1-ylpropanoylamino)acridin-3-
yl]-3-pyrrolidin-1-ylpropanamide), porphryins (e.g. TMPyP4= tetra(N-methyl-





Figure 1.11: Structures of some compounds that bind to qDNA: a) 2,6-
diamidoanthraquinone; b) TMPyP4; c) BRACO19, and d) telomestatin. 
 
NMR studies conducted by Sun et al. revealed that 2,6-
diamidoanthraquinone binds to a parallel four-stranded G-quadruplex through 
intercalation between the G-tetrads.74 Further studies conducted by 
Wheelhouse and co-workers showed that the porphyrins like TMPyP4 could 
bind to both parallel and anti-parallel q-DNA intercalatively.73,89,111 In addition, 
research has shown that both the acridine BRACO19 and the natural product 
telomestatin can bind to quadruplex DNA and act as telomerase 
inhibitors.103,112-114 All these studies have concluded that the binding of small 
molecules to G-quadruplex DNA is affected by various factors including their 
overall charge, the length of any side chains present, and hydrogen bonding 
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substituents.74 Some known double-stranded DNA binding compounds such 
as distamycin, daunomycin and ethidium bromide have also been found to 
bind to G-quadruplex DNA.115,116 Compounds that bind to both double-
stranded DNA and G-quadruplex DNA are consequently cytotoxic at the 
concentrations required to inhibit telomerase.104 Therefore, it is important to 
develop new compounds that exhibit high binding affinities and selectivity for 
quadruplex DNA, over duplex DNA. 
 
1.4 Metal complexes that bind to DNA 
During the last few decades there has been increased interest in transition 
metal complexes as potential anticancer and antibacterial therapeutics.117 
Some metal complexes have been shown to interfere with DNA replication, 
DNA transcription and apoptosis, meaning they can be used to damage DNA 
and induce cell death.43,118,119 It is well known now that the biological activity 
of some metal complexes is due to their ability to bind to DNA.30,66,120 The 
great diversity in structures and size of transition metal complexes, as well as 
their electrochemical and photophysical properties, makes them attractive as 
selective DNA binding reagents.56,121,122 Therefore, the DNA binding 
properties of a number of metal complexes have been investigated. A large 
proportion of these complexes contain ruthenium(II), rhodium(III), 
platinum(II), platinum(IV), and titanium(IV), and their DNA-binding behaviour 
has been extensively investigated both in vitro and in vivo. Much attention 
was initially directed to square planar and octahedral complexes containing 
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inert metal ions such as platinum(II), rhodium(III) and ruthenium(II) with 
bidentate or tetradentate aromatic heterocyclic ligands.121 These metal 
complexes are non-covalent DNA-binding agents that act as either groove-
binders or intercalators.121 
 
1.4.1 Metal complexes that bind to dsDNA 
Almost 35 years ago the Sigman group demonstrated that [Cu(phen)2]+, 
(phen = 1,10-phenanthroline) (Figure 1.12a) binds to DNA non-covalently by 
interacting with the DNA minor groove, and functions as a synthetic DNA 
nuclease.123 Since this demonstration many other studies have established 
that most mononuclear, inert transition metal complexes especially those 
bearing aromatic ligand bind in the minor groove of DNA. This includes 
platinum complexes such as [Pt(en)2]2+ (en= 1,2-diaminoethane), (Figure 
1.12b), and the square planar nickel(II) metallopeptide Ni(II)*Lys-Gly-His 
(Figure 1.12c), which was found to selectively associate with the dsDNA 
minor groove at A/T rich sites.124,125 Although most mononuclear, inert 
transition metal complexes act as minor groove binders, it was found that 
cobalt(III) ammine complexes such as [Co(NH3)6]3+ and [Co(en)3]3+ (Figure 
1.12d and e, respectively) selectively interact with GG sequences in the 
major groove of dsDNA.126,127 It has been proposed that the binding 
preferences of metal complexes for the major or minor groove at different 
base sequences is due to the availability of more favourable van der Waals 
interactions and electrostatic potentials, coupled with opportunities for 




Figure 1.12: Examples of mononuclear metal complexes that bind to dsDNA: 
a) [Cu(phen)2]+; b) [Pt(en)2]2+; c) Ni(II)*Lys-Gly-His; d) [Co(NH3)6]3+, and e) 
[Co(en)3]3+. 
 
While most of these complexes were found to be groove binders, a wide 
variety of metal complexes have also been found to intercalate with dsDNA. 
For example, square planar platinum(II) complexes containing an aromatic 
heterocyclic ligand such as terpy, phen, bipy, or phi, (terpy = 2,2′:6′2′′-
terpyridine, phen = phenanthroline, bipy= 2,2′-bipyridine, phi= 9,10-
phenanthrenequinone), have been shown to bind to double-stranded DNA 
noncovalently by this mechanism.128-136 The square planar geometry of Pt(II) 
complexes allows deeper insertion of attached  intercalating ligands between 
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base pairs than is possible with octahedral or tetrahedral complexes.129 
[Pt(terpy)(SCH2CH2OH)]+, (Figure 1.13a), synthesised by Lippard and co-
workers, was the first metal compound shown to bind to dsDNA by 
intercalation.130 A single crystal X-ray diffraction study revealed that 
[Pt(terpy)(SCH2CH2OH)]+ intercalated between the base pairs of double 
helical DNA.131 It was shown to intercalate into calf thymus DNA (CT-DNA) 
with a binding constant of 2x105 M-1, and to increase the length of the DNA 
as well as stabilize it.132,133 Lippard and co-workers conducted further studies 
to investigate the intercalative properties of other platinum complexes 
including [Pt(bipy)(en)]2+ and [Pt(phen)(en)]2+ (Figure 1.13b and c). X-ray 
diffraction and electrophoresis studies revealed that the planar ligands phen 
and bipy help these complexes to intercalate and unwind DNA.134-136 It was 
concluded that the intercalative ability of metal complexes depends upon 
various factors including the structural characteristics of the complex, DNA 
composition and the ionic strength of the surrounding medium.137 
 
 
Figure 1.13: Examples of platinum metallointercalators: a) [Pt(terpy)-




Another study involving platinum intercalators was conducted by Aldrich-
Wright and co-workers. They examined the effect of a series of Pt(II) 
complexes with the general formula [Pt(en)(Mexphen)]2+ (x = 1, 2 or 4) on 
L1210 leukaemia cells. Their work revealed that the DNA affinity of these 
complexes, and their activity towards the leukaemia cells, was affected by 
the number and the position of the methyl groups on the phenanthroline 
ligand.138,139 This result suggests that altering the ligand structure can 
improve the binding affinity of metal complexes towards DNA. 
Although platinum complexes were the initial focus of the majority of research 
into metal anticancer complexes, a large amount of interest now focuses on 
octahedral metallointercalators containing other transition metals. Interest in 
the interactions of octahedral transition metal centres with DNA stems in part 
from the discovery that [Ru(phen)3]2+ and related complexes can bind non-
covalently and enantioselectively to DNA.122,140 This is partially attributable to 
the greater size of the octahedral coordination sphere, which provides more 
surface area for interactions with DNA and, therefore, potentially enhances 
DNA binding selectivity. The binding properties of a wide variety of 
octahedral rhodium and ruthenium complexes containing aromatic ligands 
such as phen, phi, dppz, phzi, and eilatin (dppz = dipyrido[3,2-a:2,3-
c]phenazine, phzi = benzo[a]phenazin-5,6-quinone diimine, eilatin = 
dibenzo[b,j]dipyrido[4,3,2-de:2,3,4-gh][1,10]phenanthroline) have been 
investigated.56,141,142 
It has been found that metal complexes containing phen, phi or dppz bind to 
duplex DNA via intercalation, by inserting these ligands to different extents in 
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between two base pairs. In contrast, metal complexes containing phzioreilatin 
bind via insertion, with this ligand displacing DNA bases out of the base 
stack.56,141,142 Studies on chiral octahedral ruthenium(II) complexes such as 
[Ru(DIP)3]2+ (DIP = 4,7-diphenyl-1,10-phenanthroline) (Figure 1.14a) showed 
that the Δ-enantiomer binds more tightly to B-DNA, whilst 
[Ru(phen)2(dppz)]2+ (dppz = dipyrido[3,2-a:2,3’-c]phenazine) (Figure 1.14b) 
shows extremely high dsDNA binding affinity due to the expansive aromatic 
surface area of the dppz ligand.143,144 
 
 
Figure 1.14: Examples of some octahedral metallointercalators: a) 
[Ru(DIP)3]2+, and b) [Ru(phen)2(dppz)]2+. 
 
The inclusion of the highly intercalative dppz ligand in the coordination 
sphere of a complex has been shown to generally enhance dsDNA binding 
affinity.122,143,145 These studies concluded that the structure of the 
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intercalating ligand present in a metal complex can affect its binding modes 
and selectivity toward different DNA sequences. For example, one report by 
Urathamakul and co-workers showed that the relative affinities of some 
ruthenium complexes towards a dsDNA molecule decreased in the following 
order: [Ru(phen)2(dppz)]2+> [Ru(phen)2(dpqMe2)]2+ (dpqMe2 = 6,7-dimethyl-
2,3-di(pyridin-2-yl)quinoxaline) > [Ru(phen)2(dpqC)]2+ (dpqc = dipyrido[3,2-
a:2’3’-c](6,7,8,9-tetrahydro)phenazine) >[Ru(phen)2(dpq)]2+ (dpq = 
dipyrido[3,2-d:2’3’-f]quinozaline)> [Ru(phen)2(pda)]2+ (pda = 9,10-





Figure 1.15: Structures of dsDNA-binding Ru(II) complexes studied by 
Urathamakul and co-workers: a) [Ru(phen)3]2+; b) [Ru(phen)2(dpq)]2+; c) 
[Ru(phen)2(dppz)]2+;d) [Ru(phen)2(dpqC)]2+; e) [Ru(phen)2(dpqMe2)]2+; f) 
[Ru(phen)2(pda)]2+.143 
 
Another study conducted by Talib and co-workers found that the DNA binding 
affinity of some octahedral nickel(II) complexes with different ligands followed 
the order [Ni(phen)3]2+< [Ni(phen)2(dpq)]2+< [Ni(phen)2(dpqC)]2+< 
[Ni(phen)2(dppz)]2+.144 These studies suggest that the binding affinity of 
[M(phen)3]2+ complexes can be increased by replacing one phen ligand with 
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other aromatic bidentate ligands which have an extended polycyclic 
structure. 
Other studies have investigated the effect upon DNA binding of changing the 
identity of the metal ion present in a metallointercalator.146,147 For example, 
Arounaguiri and co-workers examined the binding affinity of complexes with 
the general structure [M(phen)2(dppz)]2+ to CT-DNA, and found that the 
binding constants for interactions of these complexes followed the trend 
Ru(II) > Co(III) > Ni(II).145 Another study conducted by Talib and co-workers 
found that octahedral nickel(II) complexes containing aromatic ligands 
interacted more weakly with DNA than the corresponding ruthenium(II) 
complexes, and attributed this to the difference in size of the metal 
complexes.144 
 
1.4.2 Metal complexes that bind to quadruplex DNA 
Although most of the reported quadruplex DNA stabilisers are purely organic 
compounds with heteroaromatic structures, recent studies have 
demonstrated that metal complexes can also bind to and stabilise quadruplex 
DNA effectively. This includes complexes in which metals are coordinated to 
planar aromatic ligands such as salphen (N,N′-
bis(salicylidene)phenylenediamine), terpyridines, and phenanthrolines. A 
manganese(III) porphyrin was the first planar metal complex to be 
investigated for its potential to act as a qDNA stabilising agent.148 This 
complex combined a central aromatic core and four flexible cationic arms 
28 
 
(Figure 1.16a), and showed a high affinity for the human telomeric 
quadruplex DNA (GGGTTA)4. It was able to discriminate between quadruplex 
DNA and two different duplex DNA molecules (GC-rich and AT-rich) by a 
factor of 1000 in favour of the quadruplex derived from the human telomeric 
sequence. In contrast, a related manganese porphyrin analogue Mn-TMPyP 
(Figure 1.16b), and the corresponding free base TMPyP, both showed high 
affinity for duplex DNA73,149-151 The high affinity and selectivity of the 
manganese(III) porphyrin shown in Figure 1.16a toward telomeric qDNA was 
found to be due to the combination of the central aromatic core and the four 
flexible cationic arms. Additional studies were conducted to investigate the 
ability of other metalloporphyrins with manganese(III) or nickel(II) centres to 
target quadruplexes formed from telomeric DNA.149,152 These showed that 
metalloporphyrins were capable of inhibiting telomerase with IC50 values in 
the micromolar range. In addition, it was found that the nature of the metal 
centre and its coordination geometry plays an important role in the kinetics of 





Figure 1.16: Structure of some metal porphyrin complexes that have been 
shown to bind to and stabilise quadruplex DNA: a) a manganese(III) 
porphyrin complex, and b) Mn-TMPyP4. 
 
A different class of quadruplex-stabilizing and telomerase-inhibiting metal 
complexes was investigated by Reed and co-workers.153 These were square 
planar platinum(II) complexes containing substituted phenanthroline ligands 
(Figure 1.17).  FRET (Fluorescence Resonance Energy Transfer) was used 
to study the interactions between these platinum(II) complexes and both 
duplex and quadruplex DNA. It was found that the platinum(II) complexes 
with the piperidine-containing ligand (Figure 1.17b) induced a high degree of 
stabilisation of quadruplex DNA formed from the human telomeric sequence, 
which indicated that the piperidine substituent had a significant positive effect 




Figure 1.17: Structure of some platinum(II) complexes shown to bind to 
quadruplex DNA by Reed and co-workers.153 
 
Reed and co-workers have also reported that some nickel(II) salphen 
complexes can act as a new type of telomeric quadruplex DNA stabiliser and 
telomerase inhibitor.154 Qualitative molecular modelling studies showed that 
these Ni(II) complexes (Figure 1.18) possess the main structural 
requirements to be quadruplex-stabilizing molecules. These include the π-
delocalized system of the salphen ligands, which can stack on a guanine 
quartet, the positively charged piperidine substituents, which interact with the 
grooves and loops and the negatively charged phosphate backbone of the 
quadruplex, and finally the positively charged nickel ion that was found to lie 
above the centre of a G-quartet.154 These planar complexes were also found 




Figure 1.18: Structure of some nickel(II) salphen complexes shown to bind to 
quadruplex DNA by Reed and co-workers.154 
 
A later study was conducted to further explore the ability of metal Schiff base 
complexes as selective qDNA binders and telomerase inhibitors. This study 
investigated the effect of changing the number of aromatic ring systems 
present in the complexes shown in Figure 1.18, or the identity of side chains, 
on their qDNA binding properties.155 In addition, the effect of changing the 
metal ion in the Schiff base complex, and therefore its overall geometry, on 
the ability to interact with the G-quadruplex DNA F21T (sequence: 5-FAM-
d(GGG[TTAGGG]3)-TAMRA-3) using a FRET melting assay, was 
explored.155 The structures of some of these complexes are presented in 
Figure 1.19. The results of the FRET assay clearly revealed that the square 
planar nickel(II) and copper(II) complexes were highly effective stabilizers of 
human telomeric DNA. It was found that the change in melting temperature 
(ΔTm) induced by nickel salphen complexes which contained different 




Figure 1.19: Structure of some of the metal Schiff base complexes whose 
qDNA-binding properties were studied by Arola-Arnal and co-workers.155 
 
These results suggested that variations in the cyclic amine substituents do 
not make significant differences in the binding affinity of these complexes. On 
the other hand, the nickel(II) salen complex in Figure 1.19a exhibited a lower 
ΔTm than the corresponding salphen complex in Figure 1.18a, which was 
attributed to the former complex having one less aromatic ring able to interact 
with a G-quartet of the quadruplex DNA molecule. It was also found that 
varying the central metal ion in the complex could dramatically affect the 
DNA binding properties. For example, despite the similar square planar 
coordination environment around the metal ion for the complexes in Figure 
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1.18a and Figure 1.19b, the ΔTm value for the copper complex was found to 
be significantly lower.155 
Furthermore, the above work revealed that the geometry of the metal 
complex had an effect on DNA-binding properties. For example, the distorted 
square pyramidal zinc and vanadium complexes (Figure 1.19c and d, 
respectively) showed negligible or little interaction with quadruplex DNA. This 
was demonstrated by their ΔTm values being considerably lower than that of 
the analogous square planar nickel and copper complexes. This indicates 
that for optimal binding between metal complexes and quadruplex DNA, the 
former must have a square planar geometry in which both faces are available 
for π-π stacking with a guanine quartet. FRET competition assays showed 
that these metal complexes have a high degree of selectivity for quadruplex 
DNA as opposed to duplex DNA. 
Recently, the nickel Schiff base complexes shown in Figure 1.20 were 
synthesized and their interactions with a duplex DNA molecule, as well as 
both tetramolecular and unimolecular DNA quadruplexes, were investigated 
using several techniques including ESI-MS, DNA melting temperature 
measurements, CD spectroscopy, and FRET assays.156 ESI-MS and DNA 
melting temperature measurements suggested that the complex in Figure 
1.20b exhibits a lower affinity than that in Figure 1.20a towards a dsDNA 
molecule. This could be attributed to inability of the former molecules to more 
effectively interact with dsDNA via an intercalation binding mode as a result 
of the two aromatic ring systems derived from meso-1,2-
diphenylethylenediamine. In contrast, the presence of a single aromatic 
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system that is coplanar with those which originated from 2,4- 
dihydroxybenzaldehyde in the complex shown in Figure 1.20a facilitates 
insertion into the stack of dsDNA base pairs.  
 
Figure 1.20: Structure of some of the metal Schiff base complexes whose 
qDNA-binding properties were studied by Davis and co-workers.156,157 
 
In addition, ESI-MS and CD spectroscopy suggested that the complex in 
Figure 1.20b shows significant binding to a tetramolecular DNA quadruplex. 
This could be attributed to the presence of additional binding sites in qDNA 
such as the terminal G-tetrads found on the ends of the nucleic acid 
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molecules, which allow for π-π stacking interactions between these nickel 
complexes and the guanine residues of the G-tetrads. Interestingly, the 
results of ESI-MS and FRET assays indicated that the nickel complex in 
Figure 1.20b did not bind as tightly to a unimolecular DNA quadruplex. These 
results indicate that the presence of the meso-1,2-diphenylethylenediamine 
moiety in metal complexes of this type may enhance their selectivity for some 
DNA quadruplexes over dsDNA. 
The size and position of the aromatic surface area within the nickel Schiff 
base complexes was found to be important for DNA binding interactions. For 
example, it was found that the complex in Figure 1.20c exhibited a high 
affinity for dsDNA, but a limited binding to qDNA molecules.157 This could be 
attributed to the presence of a large planar 9,10-diaminophenanthrene unit 
which facilitates insertion into the stack of dsDNA base pairs, but sterically 
hinders the approach of the nickel Schiff base molecules to the loops of the 
qDNA molecule. In addition, ESI-MS, CD spectroscopy and UV-Vis DNA 
melting studies suggested that the asymmetric complex shown in Figure 
1.20d which contained a single naphthaldehyde moiety, exhibited a 
significant decrease in its ability to bind to dsDNA, as well as a limited 
binding to qDNA.157  This result could be attributed to the lack of the 
electrostatic interactions due to the presence of only one piperidine group 
that can be protonated in the solution, as well as the presence of the 
naphthaldehyde unit which may hinder the approach of the nickel Schiff base 
molecules to the dsDNA and to G-quadruplexes. Furthermore, the effect of 
changing the length or chemical composition of side chains present in the 
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complexes shown in Figure 1.20, upon their DNA binding properties was also 
explored.157 Both ESI-MS and CD spectroscopy studies revealed that the 
replacement of the alkyl chains by either propyl piperidine or ethyl morpholine 
did not result in any significant enhancements in DNA affinity or selectivity. 
 
1.5 Aims 
The results of studies described in the previous section indicate that 
changing the structure of nickel Schiff base complexes can enhance their 
binding affinity and selectivity for qDNA. These changes included increasing 
the number of aromatic moieties present in their structure, and the length and 
chemical composition of the pendant groups. However, to date, the effect of 
varying the position of the pendant groups on the ability of those complexes 
to bind to qDNA and their selectivity for qDNA over dsDNA, has not been 
explored. 
Therefore, the aims of this project were to: 
1. Synthesize the hydroxylated nickel Schiff base complexes shown in 
Figure 1.21. 
2. Synthesize the alkylated nickel Schiff base complexes (7) – (12) 
shown in Figure 1.22 by reacting the complexes in Figure 1.21 with 1-
(2-chloroethyl)piperidine hydrochloride. These complexes are isomers 
of those shown in Figure 1.18a, Figure 1.19a, and Figure 1.20a. The 
source of isomers stems from the identity of the 
dihydroxybenzaldehyde (2,3- or 2,5- isomer, as opposed to 2,4-
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isomer) used during the first stage of synthetic procedure used to 
prepare the metal complex. 
 
Figure 1.21: Structures of the hydroxylated nickel Schiff base complexes 
synthesized in this study. 
 
3. Characterize the above complexes by mass spectrometry, as well as 
NMR spectroscopy, microanalysis and, where possible, X-ray 
crystallography. 
4. Use electrospray ionization mass spectrometry and circular dichroism 
spectroscopy to compare the interactions between the nickel Schiff 
base complexes shown in Figure 1.22 with a duplex DNA molecule 
(D2) and a tetramolecular quadruplex DNA (Q4), with that of the 









CHAPTER 2  
MATERIALS AND METHODS 
 
2.1 Chemicals 
All solvents and reagents used in this study were of the highest grade 
commercially available. Milli-QTM water (Millipore, Molsheim, France) was 
used in all experiments. Nickel compounds (13), (14) and (15) were obtained 
from PhD student Kimberley Davis (School of Chemistry, University of 
Wollongong, Australia). 1-(2-Chloroethyl)piperidine hydrochloride, 2,3-
dihydroxybenzaldehyde, 2,5-dihydroxybenzaldehyde, magnesium sulfate 
(MgSO4), 1,2-phenylenediamine, 1,2-ethylenediamine, 1,2-meso-
diphenylethylenediamine, nickel acetate tetrahydrate (Ni(OAc)2·4H2O), 
DMSO-d6 ((CD3)2SO), CDCl3 and cesium iodide (Fluka brand) were all 
purchased from Sigma-Aldrich (Castle Hill, Australia). Potassium carbonate 
(K2CO3), dimethylformamide (DMF), dichloromethane (DCM), dimethyl 
sulfoxide (DMSO), acetic acid (CH3COOH), methanol (MeOH), anhydrous 
diethyl ether (Et2O), aluminium oxide used in column chromatography, as 
well as acetonitrile (ACN), ammonia and ammonium acetate (NH4OAc) that 
were used in HPLC purification of oligonucleotides and ESI-MS experiments, 
were all purchased from Ajax Finechem (Seven Hills, Australia). All 
oligonucleotides were obtained either from Geneworks (Adelaide, South 




2.2 Characterisation of nickel Schiff base complexes 
2.2.1 Physical measurements 
 
Elemental microanalysis determination for the elements carbon, hydrogen, 
nitrogen and nickel were performed at the Campbell Microanalytical 
Laboratory at the Chemistry Department of the University of Otago, New 
Zealand. NMR spectra of the nickel complexes dissolved either in DMSO-d6 
or CDCl3 were obtained using a Varian Inova-500 MHz NMR spectrometer at 
25 °C. The chemical shifts of the resonances observed in 1H and 13C NMR 
spectra were reported in ppm (δ) relative to either tetramethylsilane (TMS) or 
the solvent peak as an internal standard. In 1H NMR spectra, the signal from 
the small amount of CHCl3 present in CDCl3 solvent was reported at 7.26 
ppm, while the signal from the small amount of CD3SOCD2H present in 
DMSO-d6 solvent was reported at 2.50 ppm. For 13C NMR spectra, the 
resonance from the CDCl3 solvent was set to 77.7 ppm, while that from 
DMSO-d6 solvent was assigned to 39.6 ppm. Hydrogen and carbon 
resonances were fully assigned through the use of 2D experiments including 
Correlation Spectroscopy (COSY), Nuclear Overhauser Effect Spectroscopy 
(NOESY), Heteronuclear Single-Quantum Correlation (HSQC) and 
Heteronuclear Multiple-Bond Correlation (HMBC) spectroscopy. Electrospray 
ionisation (ESI) mass spectra of alkylated nickel Schiff base complexes were 
obtained using a Waters Quattro ESI mass spectrometer (Milford, 






X-ray structural studies were performed by Dr Anthony C. Willis at the 
Research School of Chemistry, the Australian National University, Canberra, 
Australia. The X-ray diffraction measurements performed on complexes (5), 
(8) and (10) were carried out at 150 K on an Xcalibur diffractometer with 
Atlas detector using Mo Kα radiation, λ = 0.71073 Å. Data reduction and cell 
refinement were accomplished using CrysAlis PRO software.158 The 
structures were solved with SIR92, and refined using the program 
CRYSTALS.159,160 Molecular graphics were produced using PLATON.161 
During refinement of (5) hydrogen atoms bonded to C were positioned 
geometrically and the water H atoms were based on peaks from a difference 
electron density map and potential H-bonded contacts. The H atoms were 
initially refined with soft restraints on the bond lengths and angles to 
regularize their geometry (C-H in the range 0.93-0.98 Å, O-H = 0.82 Å) and 
with Uiso(H) in the range 1.2-1.5 times Ueq of the parent atom, after which the 
positions were refined with riding constraints. 
During refinement of (8), the H atoms were all located in a difference map, 
but those bonded to C were repositioned geometrically. The H atoms were 
initially refined with soft restraints on the bond lengths and angles to 
regularize their geometry (C-H in the range 0.93-0.98 Å, O-H = 0.83 Å) and 
with Uiso(H) in the range 1.2-1.5 times Ueq of the parent atom, after which the 
positions were refined with riding constraints except for those bonded to O 
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which were allowed to refine freely. The largest features in the final difference 
electron density map are located midway between bonded atoms. 
During refinement of (10) the program PLATON was used to identify a 
twinning relationship in the data. Application of a twinning correlation within 
CRYSTALS to allow for overlapping reflections, based on the above 
relationship, gave a small improvement in the agreement factors. The final 
refined values for the twin elements were 0.704(5) and 0.296(5). Hydrogen 
atoms bonded to C were positioned geometrically and the water H atoms 
were based on peaks from a difference electron density map and potential H-
bonded contacts. The H atoms were initially refined with soft restraints on the 
bond lengths and angles to regularize their geometry (C-H in the range 0.93-
0.98 Å, O-H = 0.82 Å) and with Uiso(H) in the range 1.2-1.5 times Ueq of the 
parent atom, after which the positions were refined with riding constraints. 
 
2.3  Oligonucleotides 
2.3.1 Purification of single-stranded oligonucleotides 
 
Single-stranded oligonucleotides (D2A, D2B and q4) were purchased from 
either Sigma-Aldrich (Castle Hill, Australia), or Geneworks (South Australia), 
as freeze-dried ‘trityl-off’ derivatives. The base sequences of DNA molecules 
which were used in this study are presented in Table 2.1. These 
oligonucleotides were purified using high performance liquid chromatography 
(HPLC) by following previously reported procedures.157,162,163 Purified DNA 
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solutions were then freeze-dried using a Savant speedVac (Selby-Biolab, 
Australia) prior to storage at -20 °C.  
When required, freeze-dried samples were dissolved in 1000 μL of Milli-QTM 
water. Diluted solutions (300× dilution factor) were prepared by adding 2 μL 
of one of the above DNA solutions to 598 μL of Milli-QTM water. In order to 
determine the concentration of the final DNA solutions, the absorbance at 
260 nm was measured, and the molar absorbtion coefficients (ε) of the 
individual nitrogenous bases present in the DNA sequence were used to 
obtain an overall value of ε for the oligonucleotide itself. Values of ε for the 
purine and pyrimidine bases were obtained from the website, 
Oligonucleotides Properties Calculator.164  
 
Table 2.1: Properties of the DNA molecules used in this study. 




GCTGCCAAATACCTCC D2A 4786.2 
GGAGGTATTTGGCAGC D2B 4977.3 
(GCTGCCAAATACCTCC/GGAGGTATTTGGCAGC) D2 9763.5 
TTGGGGGT q4 2496.7 
(TTGGGGGT)4 Q4 9986.6 
 
2.3.2 Preparation of dsDNA (D2) 
 
Appropriate quantities of single-stranded DNA (ssDNA) solutions (D2A and 
D2B) were mixed together in an Eppendorf tube and dried using the Savant 
SpeedVac before being dissolved in an appropriate volume of NH4OAc 
solution (100 mM, pH 7.4) to give a final dsDNA concentration of 1 mM. The 
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DNA was then annealed by heating the resulting DNA solution in a water 
bath at 61 °C (the melting temperature of the DNA plus 15 °C)164 for 15 min, 
after which it was allowed to cool slowly to room temperature overnight.  
2.3.3 Preparation of qDNA (Q4) 
 
An appropriate quantity of solution containing the ssDNA q4 was placed in an 
Eppendorf tube, dried and then redissolved in sufficient NH4OAc solution 
(150 mM, pH 7.4) to give a final concentration of 1 mM. The DNA was then 
annealed by heating the resulting solution in a water bath at 90 °C for 15 min, 
after which it was allowed to cool slowly to room temperature overnight.   
 
2.4 Reactions of oligonucleotides with nickel Schiff 
base complexes 
2.4.1 ESI-MS experiments 
 
Stock solutions of nickel complexes (1 mM) were prepared in a mixture of 
acetic acid:MeOH (1:99) for all DNA-binding studies. Reaction mixtures 
containing different ratios of DNA (10 μM) and nickel complex were prepared 
in NH4OAc solution (100 and 150 mM for D2 and Q4, respectively). This 
gave mixtures with final DNA:metal complex ratios of 1:1, 1:3, 1:6 and 1:9. 
The volumes of different reagent solutions used to prepare these reaction 




Table 2.2: Volume of stock solutions used to prepare nickel/DNA samples for 
analysis by ESI-MS. 
DNA:metal 
complex ratio 
Volume of DNA 









1:1 1 1 98 
1:3 1 3 96 
1:6 1 6 93 
1:9 1 9 90 
 
ESI-MS was used to investigate the binding of nickel complexes to dsDNA 
and qDNA. A Waters Q-ToF UltimaTM ESI mass spectrometer (Manchester, 
UK) was used to acquire mass spectra in negative ion mode. The instrument 
was calibrated using a cesium iodide (CsI) solution (1 mg/mL), prior to 
acquiring the spectra of samples containing DNA and nickel complexes. The 
samples were injected into the mass spectrometer using a Harvard model 22 
syringe pump (Natick, USA) at a constant flow rate (10 μL/min). The 
parameters used to obtain the spectra for all experiments are listed in Table 
2.3. 
 
Table 2.3: ESI-MS conditions used for the analysis of DNA/metal complex 
solutions. 
MS parameter Setting 
Capillary (kV) 2.50 
Cone (V) 60 
Source temperature (°C) 25 
Desolvation temperature (°C) 80 




2.4.2 CD Experiments 
 
 A Jasco J-810 spectropolarimeter and 0.1 cm path length quartz cell was 
used to obtain CD spectra between 200 and 400 nm. The instrument 
parameters used to acquire these spectra are listed in Table 2.4.  
Table 2.4: Instrument parameters used to acquire all CD spectra of nickel/ 
DNA samples. 
CD parameter Setting 
Sensitivity standard 
Scanning speed 100 nm/min 
Response 4 s 
Band width 1 nm 
Number of accumulations 6 
Temperature  25 °C 
 
The CD spectra were obtained first for a 300 μL solution containing either D2 
or Q4 (20 μM) dissolved in NH4OAc solution of the appropriate concentration. 
Aliquots of a stock solution (Table 2.5) containing both the same type of DNA 
(20 μM) and nickel complex (0.6 mM), were then added to the initial DNA 
solution in order to produce samples with DNA:metal complex ratios of 1:1, 
1:3, 1:6 and 1:9. CD spectra were obtained after each new solution was 
made. 
Table 2.5: Volumes of the DNA/metal complex stock required for CD 
samples. 
DNA: metal complex ratio Volume of DNA/nickel complex stock 








CHAPTER 3  
SYNTHESIS AND CHARACTERISATION 
OF NICKEL SCHIFF BASE COMPLEXES. 
 
3.1 Synthesis of hydroxylated nickel Schiff base 
complexes  
N, N′-Bis-5-(hydroxysalicylidine)ethylenediaminenickel(II) (1)  
 
 
This compound was prepared by following a previously reported method.155 
2,5-Dihydroxybenzaldehyde (676 mg, 4.89 mmol) and 1,2-ethylenediamine 
(197 mg, 3.30 mmol) were dissolved in MeOH (50 mL), forming a transparent 
light orange solution. The mixture was heated with constant stirring under 
reflux for 30 min, after which Ni(OAc)2·4H2O (1.24 g, 4.96 mmol) was added, 
forming a chocolate brown coloured precipitate. Refluxing was continued for 
another 3 h. After this time, the solution was allowed to cool to room 
temperature. The red-brown solid present was collected by vacuum filtration, 
and then washed with MeOH (100 mL), diethyl ether (50 mL) and water (50 
mL). The compound was then dried under vacuum for a further 1 h. Yield: 
0.81 g, 92.0 %. Microanalysis calc. for C16H14N2NiO4·4H2O: C = 44.80; H = 
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5.17; N = 6.53; Ni = 13.68 %. Found: C = 44.83; H = 4.25; N = 6.53; Ni = 
14.00 %. 1H NMR (500 MHz, DMSO-d6): δ 3.36 (s, 4H, H1); 6.55 (d, 2H, J = 
8.74 Hz, H7); 6.58 (d, 2H, J = 2.38 Hz, H4); 6.73 (dd, 2H, J = 2.39 and 8.74 
Hz, H6); 7.77 (s, 2H, H2); 8.55 (s, 2H, OH); 13C NMR (125 MHz, DMSO-d6): δ 
58.36 (C1); 115.09 (C4); 119.57 (C3); 120.47 (C7); 124.43 (C6); 146.18 (C5); 
158.72 (C8); 162.42 (C2); 
N, N′-Bis-5-(hydroxysalicylidine)phenylenediaminenickel(II) (2) 
 
 
This compound was prepared by following a previously reported method.154 
2,3-Dihydroxybenzaldehyde (695 mg, 5.03 mmol)  and 1,2-phenylenediamine 
(239 mg, 2.21 mmol)  were dissolved in MeOH (50 mL), forming a 
transparent light yellow solution. This was heated under reflux with constant 
stirring for 30 min, during which time the solution changed to a dark orange 
colour. Ni(OAc)2·4H2O (1.27 g, 5.09 mmol) was subsequently added, and a 
dark red-brown precipitate formed immediately. The reaction mixture was 
heated under reflux for a further 3 h, after which the solution was allowed to 
cool to room temperature. The precipitate that remained was collected by 
vacuum filtration and then washed sequentially with MeOH (100 mL), diethyl 
ether (50 mL) and water (50 mL). The compound was then dried under 
vacuum for 2 h. Yield: 1.00 g, 98.0 %. Microanalysis calc. for 
C20H14N2NiO4·1.25H2O: C =56.19; H =3.89; N = 6.55 %. Found: C =56.14; H 
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= 3.68; N = 6.49 %. 1H NMR (500 MHz, DMSO-d6): δ 6.76 (d, 2H, J = 8.7 Hz, 
H9); 6.90 (s, 2H, H6); 6.92 (broad s, 2H, H8); 7.29 (m, 2H, H1); 8.13 (m, 2H, 
H2); 8.80 (s, 2H, H4); 8.82 (s, 2H, OH). 13C NMR (125 MHz, DMSO-d6): 
115.15 (C6); 116.44 (C2); 119.51 (C5); 121.07 (C9); 127.25 (C8); 127.57 
(C1); 142.81 (C3); 146.78 (C7); 155.71 (C4); 160.80 (C10). 
N, N′-Bis-5-(hydroxysalicylidine)meso-diphenylethylenediaminenickel(II) (3)  
 
 
2,5-Dihydroxybenzaldehyde (675 mg, 4.89 mmol) and 1,2-meso-
diphenylethylenediamine (537 mg, 2.53 mmol) were dissolved in MeOH (50 
mL), forming a transparent light yellow solution. This was heated under reflux 
with constant stirring for 30 min. During this time the solution changed to an 
orange colour. Ni(OAc)2·4H2O (1.24 g, 4.96 mmol) was subsequently added, 
and a dark green precipitate formed immediately. This solution was heated 
under reflux for a further 3 h. After the solution was allowed to cool to room 
temperature, the precipitate was isolated by vacuum filtration and dried. The 
green solid was then washed with MeOH (100 mL), diethyl ether (50 mL) and 
water (50 mL), before being dried under vacuum for a further 1 h. Yield: 0.98 
g, 79.0 %. Microanalysis calc. for C28H22N2NiO4·2H2O: C = 61.69; H = 4.81; 
N = 5.14; Ni = 10.77 %. Found: C = 61.72; H = 4.57; N = 5.14; Ni = 11.00 %. 
1H NMR (500 MHz, DMSO-d6): δ 5.02 (s, 2H, H7); 6.40 (d, 2H, J = 2.6  Hz, 
H10); 6.62 (d, 2H, J = 9.1 Hz, H13); 6.78 (dd, 2H, J = 2.7, 9.00 Hz, H12); 
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7.27 (m, 6H, H2, 3 and 4); 7.40 (broad s, 4H, H1 and 5); 7.45 (s, 2H, H8); 
8.52 (s, 2H, OH); 13C NMR (125 MHz, DMSO-d6): δ 76.40 (C7); 115.06 
(C10); 119.44 (C9); 120.63 (C13); 125.23 (C12); 128.70 (C3); 128.83 (4C, 
C2 and C4); 129.60 (4C, C1 and C5); 136.38 (C6); 146.40 (C11); 159.07 
(C14); 162.34 (C8). 
N, N′-Bis-3-(hydroxysalicylidine)ethylenediaminenickel(II) (4) 
 
 
This compound was prepared by following a previously reported method.155 
2,3-Dihydroxybenzaldehyde (676 mg, 4.89 mmol) and 1,2-ethylenediamine 
(197 mg, 3.27 mmol) were dissolved in MeOH (50 mL), forming a light yellow 
suspension. This stirred reaction mixture was heated under reflux for 30 min, 
during which time the solution colour changed to dark orange. 
Ni(OAc)2·4H2O (1.24 g, 4.96 mmol)  was then added, and a dark green 
precipitate formed immediately. This mixture was heated under reflux for a 
further 3 h. After the reaction was completed, the mixture was allowed to cool 
to room temperature, and the green solid isolated by vacuum filtration and 
dried. It was then washed with MeOH (100 mL), diethyl ether (50 mL) and 
water (50 mL), before being dried under vacuum for a further 2 h. Yield: 0.70 
g, 80.0 %. Microanalysis calc. for C16H14N2NiO4·H2O: C = 51.25; H = 4.30; N 
= 7.47; Ni = 15.65 %. Found: C = 51.09; H = 3.94; N = 7.43; Ni = 15.60 %.1H 
NMR (500 MHz, DMSO-d6): δ 3.43 (s, 4H, H1); 6.38 (t, 2H, J = 7.68 Hz, H5); 
6.69 (dd, 2H, J = 1.54 and 7.49 Hz, H6); 6.74 (dd, 2H, J =1.53 and 8.06 Hz, 
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H4); 7.88 (s, 2H, C2); 8.16 (broad s, OH). 13C NMR (125 MHz, DMSO-d6): δ 
58.45 (C1); 114.81 (C5); 114.95 (C6); 119.61 (C3); 122.40 (C4); 148.15 (C7); 
153.13 (C8); 163.21 (C2). 
N, N′-Bis-3-(hydroxysalicylidine)phenylenediaminenickel(II) (5) 
 
 
2,3-Dihydroxybenzaldehyde (695 mg, 5.03 mmmol) and 1,2-
phenylenediamine (284 mg, 2.63 mmol) were dissolved in MeOH (50 mL), 
forming a transparent dark yellow solution. This was heated for 30 min at 
reflux with constant stirring, during which time the solution colour changed to 
dark orange. Ni(OAc)2·4H2O (1.27 g, 5.10 mmol) was then added to the 
mixture, and immediately resulted in a deep red-brown precipitate. This 
solution continued to be heated under reflux for 3 h, after which it was 
allowed to cool to room temperature. The precipitate that had formed was 
separated by vacuum filtration and dried. It was subsequently washed with 
MeOH (100 mL), diethyl ether (50 mL) and water (50 mL), before being dried 
under vacuum for a further 2 h. Yield: 0.69 g, 68.0 %. The product was 
purified by crystallization from a MeOH-DMSO (70:30) mixture. Microanalysis 
calc. for C20H14N2NiO4·2H2O: C = 54.47; H = 4.11; N = 6.35; Ni = 13.31%. 
Found: C = 54.57; H = 3.48; N = 6.22; Ni = 13.20 %.1H NMR (500 MHz, 
DMSO-d6): δ 6.54 (t, 2H, J = 7.63 Hz, H7); 6.81 (d, 2H, J = 6.67 Hz, H8); 7.09 
(d, 2H, J = 8.10 Hz, H6); 7.35 (m, 2H, H1); 8.17 (m, 2H, H2); 8.51 (s, 2H, 
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H4); 9.12 (s, 2H, OH). 13C NMR (125 MHz, DMSO-d6): δ 115.84 (C7); 116.13 
(C8); 116.83 (C2); 119.70 (C5); 123.88 (C6); 128.12 (C1); 142.66 (C3); 
148.66 (C9); 154.99 (C10); 157.21 (C4). 
N, N′-Bis-3-(hydroxysalicylidine) meso-diphenylethylenediaminenickel(II) (6) 
 
 
2,3-Dihydroxybenzaldehyde (676 mg, 4.89 mmol) and 1,2-meso-
diphenylethylenediamine (537 mg, 2.53 mmol) were dissolved in MeOH (50 
mL), forming a transparent light yellow solution. The mixture was heated with 
constant stirring under reflux for 30 min. During this time the solution 
changed colour to dark orange. Ni(OAc)2·4H2O (1.23 g, 4.96 mmol)  was 
added to the reaction mixture, and a dark green precipitate formed 
immediately. Heating under reflux was continued for another 3 h, after which 
the solution was allowed to cool to room temperature, and the resulting 
precipitate was isolated by vacuum filtration. The solid was then washed with 
MeOH (100 mL), diethyl ether (50 mL) and water (50 mL), before being dried 
under vacuum for a further 2 h. Yield: 1.20 g, 97.0 %. Microanalysis calc. for 
C28H22N2NiO4·1.5H2O:  C = 62.72; H = 4.70; N = 5.22 %. Found: C = 62.68; 
H = 4.41; N = 5.19 %. 1H NMR (500 MHz, DMSO-d6): δ 5.08 (broad, s, 2H, 
H7); 6.34 (t, 2H, J = 8.03 Hz, H11); 6.61 (d, 2H, J = 6.76 Hz, H10); 6.70 (d, 
2H, J = 5.91 Hz, H12); 7.26-7.28 (m, 6H, H2, H3 and H4); 7.42 (br, s, (4H, 
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H1 and H5 ); 7.57 (s, 2H, C8); 8.34 (s, 2H, OH). 13C NMR (125 MHz, DMSO-
d6): δ 76.72 (C7); 115.33 (C11); 115.71 (C12); 119.74 (C9); 122.97 (C10); 
128.98 (C3); 129.13 (C2 and C4); 129.83 (C1 and C5); 136.35 (C6); 148.37 
(C13); 153.73 (C14); 163.45 (C8). 
 





A suspension of compound (1) (107 mg, 0.30 mmol), 1-(2-chloroethyl) 
piperidine hydrochloride (216 mg, 1.17 mmol) and K2CO3 (284 mg, 2.05 
mmol) was made in anhydrous DMF (10 mL) and stirred for 72 h under N2. 
During this time a green precipitate appeared in the bright brown solution. 
After the end of the reaction, the DMF was removed from the mixture under 
low pressure to yield a dark green solid. This was then dissolved in DCM (30 
mL), and insoluble material removed by gravity filtration. The filtrate was then 
washed with water seven times, and then dried using MgSO4, before the 
DCM was allowed to evaporate. The desired compound was subsequently 
obtained as a dark green solid. Yield 0.11 g, 63.0 %. ESI-MS calc. 
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[C30H40N4O4Ni+H]+ = 579.4, [C30H40N4O4Ni+2H]2+ = 289.7. Found: 
[C30H40N4O4Ni+H]+ = 579.1, [(C30H40N4O4Ni + 2H)]2+= 290.2. Microanalysis 
calc. for C30H40N4NiO4: C = 62.20; H = 6.96; N = 9.67 %. Found: C = 62.18; 
H = 6.98; N = 9.53 %.1H NMR (500 MHz, CDCl3): δ 1.45 (m, 4H, H13); 1.60 
(m, 8H, H12); 2.48 (broad s, 8H, H11); 2.71 (t, 4H, J = 6.04 Hz, H10); 3.41 (s, 
4H,  H1); 3.97 (t, 2H, J = 6.04 Hz, H9); 6.46 (d, 2H, J = 2.66 Hz, H4); 6.90 
(dd, 2H, J = 2.66 and 9.29 Hz, H6); 6.94 (d, 2H, J = 9.18 Hz, H7); 7.35 (s, 
2H, H2). 13C NMR (125 MHz CDCl3): δ 24.18 (C13); 25.90 (C12); 55.05 
(C11); 58.07 (C10); 58.44 (C1); 66.70 (C9); 112.99 (C4); 118.47 (C3); 122.57 





This compound was prepared by following a previously reported method.154 
Compound (2) (122 mg, 0.30 mmol) was suspended in anhydrous DMF (10 
mL), along with 1-(2-chloroethyl)piperidine hydrochloride (215.7 mg, 1.17 
mmol) and K2CO3 (284 mg, 2.05 mmol) and stirred for 72 h under N2. During 
this time a brown precipitate appeared, and the K2CO3 disappeared. After the 
end of the reaction time, the DMF was removed from the mixture under low 
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pressure to yield a red-brown solid. This was then dissolved in DCM (30 mL) 
and washed with water five times, and then dried using MgSO4, before the 
DCM was allowed to evaporate under low pressure to yield a dark red-brown 
crystalline product. Yield: 0.10 g, 53.0 %. ESI-MS calc: [C34H40N4O4Ni+H]+ = 
628.4, [C34H40N4O4Ni+2H]2+ = 314.7. Found: [C34H40N4O4Ni+H]+ = 627.2, 
[C34H40N4O4Ni +2H]2+ = 314.2. Microanalysis calc. for C34H40N4NiO4·2H2O: C 
= 61.56; H = 6.68; N = 8.44; Ni = 8.85 %. Found: C = 61.37; H = 6.52; N = 
8.13; Ni = 8.70 %. 1H NMR (500 MHz, CDCl3): δ 1.47 (m, 4H, H15); 1.63 (t, 
8H, J = 5.57 Hz, H14); 2.51 (broad s, 8H, H13); 2.75 (t, 4H, J = 6.16 Hz, 
H12); 4.04 (t, 4H, J = 6.16 Hz, H11); 6.68 (d, 2H, J = 2.64 Hz, H6); 7.02 (dd, 
2H, J = 2.93 and 9.38 Hz, H8); 7.09 (d, 2H, J = 9.38 Hz, H9); 7.18-7.20 (m, 
2H, J = 2.93, H1); 7.69-7.71 (m, 2H, J = 3.51 Hz, H2); 8.16 (s, 2H, H4). 13C 
NMR (125 MHz, CDCl3): δ 24.35 (C15); 26.09 (C14); 55.23 (C13); 58.19 
(C12); 66.85 (C11); 112.43 (C6); 114.85 (C2); 118.56 (C5); 123.33 (C9); 
127.29 (C1); 127.59 (C8); 142.89 (C3); 149.18 (C7); 153.28 (C4); 162.80 







The synthesis of this complex was monitored using thin layer 
chromatography (TLC). A suspension of compound (3) (166 mg, 0.3 mmol), 
1-(2-chloroethyl) piperidine hydrochloride (222 mg, 1.2 mmol) and K2CO3 
(294 mg, 2.1 mmol) in anhydrous DMF (10 mL) was stirred for 6 d under N2. 
TLC analysis showed that after this time the starting material was still present 
in the reaction mixture. Therefore, the reaction was heated to 50 °C for a 
further 48 h under N2 at 50 °C. The reaction was stopped after 48 h when 
TLC showed that no starting material remained in the mixture. After this time, 
the precipitate present was removed by gravity filtration. The DMF was then 
evaporated under low pressure to yield a red solid, which was then dissolved 
in DCM (30 mL), and washed with water seven times. All precipitates which 
appeared during the washing process were removed by gravity filtration. 
After the washing step, the DCM solution was dried with MgSO4, and 
evaporated yielding 0.05 g of a red solid. An ESI mass spectrum of the 
resulting solid dissolved in MeOH:H2O (50:50)) did not show any ions which 
could be assigned to complex (9). In addition, the 1H NMR spectrum of the 
product contained many broad and overlapping signals, indicating that it was 
57 
 
likely to be a mixture of compounds. In other attempts to synthesise complex 
(9), the same procedure as above was followed but different concentrations 
of either the hydroxylated precursor complex or 1-(2-chloroethyl) piperidine 
hydrochloride were used. Again ESI mass spectra and 1H NMR spectra did 
not show any sign of complex (9) in the products obtained. After these failed 
attempts to synthesise complex (9), it was decided to remove this compound 






A suspension of compound (4) (107 mg, 0.30 mmol), 1-(2-chloroethyl) 
piperidine hydrochloride (216 mg, 1.17 mmol) and K2CO3 (283 mg, 2.05 
mmol) was made in anhydrous DMF (10 mL) and stirred for 72 h under N2. 
During this time, a dark yellow precipitate appeared, and the K2CO3 
disappeared. Upon completion of the reaction, the DMF was removed under 
low pressure to yield a red solid, which was dissolved in DCM (30 mL). After 
removal of some insoluble materials by gravity filtration, the filtrate was 
washed with water five times, dried with MgSO4 and the DCM evaporated, to 
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yield a brown solid. Yield: 90.0 mg, 53.0 %. ESI-MS calc: [C30H40N4O4Ni+H]+ 
= 579.4, [C30H40N4O4Ni+2H]2+ = 289.7. Found: [C30H40N4O4Ni+H]+ = 579.1, 
[C30H40N4O4Ni + 2H]2+ = 290.2. Microanalysis calc. for C30H40N4NiO4·2H2O: 
C = 58.56; H = 7.21; N = 9.10; Ni = 9.54 %. Found: C = 58.31; H = 7.04; N = 
8.96; Ni = 9.40 %. 1H NMR (500 MHz, CDCl3): δ 1.45 (broad s, 4H, H13); 
1.64 (m, 8H, H12); 2.56 (broad s, 8H, H11); 2.93 (t, 4H, H10); 3.40 (s, 4H, 
H1); 4.13 (t, 4H, H9); 6.45 (t, 2H, J = 7.40 Hz, H5); 6.72 (d, 2H, J = 7.40 Hz, 
H4); 6.76 (d, 2H, J = 6.87 Hz, H6); 7.49 (s, 2H, H2). 13C NMR (125 MHz, 
CDCl3): δ 24.31 (C13); 25.96 (C12); 55.27 (C11); 57.61 (C10); 58.54 (C1); 
66.11 (C9); 113.96 (C5); 114.56 (C6); 120.18 (C3); 124.14 (C4); 149.95 (C7); 





A suspension of compound (5) (122 mg, 0.3 mmol), 1-(2-
chloroethyl)piperidine hydrochloride (216 mg, 1.17 mmol) and K2CO3 (284 
mg, 2.05 mmol) in anhydrous DMF (10 mL) was stirred for 96 h under N2. 
After this time, the DMF was removed from the reaction mixture under low 
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pressure to yield a red solid. This was subsequently added to DCM (30 mL), 
and the insoluble portion was removed by gravity filtration. The filtrate was 
then washed with water five times, and dried with MgSO4, before the DCM 
was removed under low pressure to afford the product as a dark red solid. 
Yield: 0.05 g, 26.0 %. ESI-MS cal: [C34H40N4O4Ni+H]+ = 628.4, 
[C34H40N44O4Ni+2H]2+ = 314.7. Found: (C34H40N4O4Ni+H)]+ = 627.2, 
[C34H40N4O4Ni+2H]2+ = 314.3. Microanalysis calc. for C34H40N4NiO4·H2O: C = 
61.56; H = 6.68; N = 8.44 %. Found: C = 61.62; H = 6.38; N = 8.37 %. 1H 
NMR (500 MHz, CDCl3): δ 1.46 (m, 4H, H15); 1.61 (m, 8H, H14); 2.56 (s, 8H, 
H13); 2.96 (t, 2H, J = 6.72, H12); 4.14 (t, 2H, J = 6.72 Hz, H11); 6.56 (t, 2H, J 
= 7.68 Hz, H7); 6.79 (d, 2H, J = 7.36 Hz, H8); 6.95 (d, 2H, J = 7.68 Hz, H6); 
7.21-7.22 (m, 2H, H1); 7.69-7.70 (m, 2H, H2); 8.24 (s, 2H, H4); 13C NMR 
(125 MHz, CDCl3): δ 24.30 (C15); 25.96 (C14); 55.29 (C13);  57.60 (C12); 
66.08 (C11); 114.82 (C2); 115.19 (C7); 115.3 (C8); 119.85 (C5); 124.64 (C6); 







A suspension of compound (6) (165 mg, 0.3 mmol), 1-(2-
chloroethyl)piperidine hydrochloride (221 mg, 1.2 mmol), and K2CO3 (292 
mg, 2.1 mmol) in anhydrous DMF (25 mL) was stirred for 72 h under N2. The 
reaction was monitored by TLC. After the end of this period, the DMF was 
removed from the reaction mixture under low pressure to yield a dark brown 
slurry. This was then dissolved in DCM (30 mL), and the resulting solution 
filtered under gravity to eliminate excess insoluble starting materials. The 
filtrate was then washed with water seven times, and dried with MgSO4, 
before the DCM was evaporated to afford the desired product as a yellowish 
brown solid. This product was purified by using column chromatography on 
alumina, using DCM/methanol (95/5, v/v) as the eluent, to yield the desired 
compound (0.11 g, 46.0 %). ESI-MS cal: [C42H48N4O4Ni+H]+ = 731.6, 
[C42H48N4O4Ni+2H]2+ = 365.8. Found: [C42H48N4O4Ni+H]+ = 731.4, 
[(C42H48N4O4Ni + 2H)]2+ = 366.3. Microanalysis calc. for C42H48N4NiO4·H2O: 
C = 67.30; H = 6.72; N = 7.47 %. Found: C = 67.40; H = 6.67; N = 7.54 %. 1H 
NMR (500 MHz, CDCl3): δ 1.45-1.46 (m, 4H, H19); 1.63 (m, 8H, H18); 2.56 
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(m, 8H, H17); 2.96 (t, 4H, J = 6.61 Hz, H16); 4.14 (t, 4H, J = 6.60 Hz, H15); 
4.77 (s, 2H, H7); 6.38 (t, 2H, J = 7.73 Hz, H11); 6.52 (d, 2H, J = 7.89 Hz, 
H10); 6.74 (d, 2H, J = 7.61 Hz, H12); 7.22 (t, 4H, H1 and H5); 7.26-7.28 (m, 
6H, H2, H4 and H8); 7.38 (broad s, 2H, H3). 13C NMR (125 MHz, CDCl3): δ 
24.25 (C19); 25.92 (C18); 55.25 (C17); 57.58 (C16); 65.95 (C15); 77.23 (C7); 
114.20 (C11); 114.86 (C12); 129.00 (C9); 124.08 (C10); 128.43 (C2 and C4); 
128.81 (C1 and C5); 129.53 (C3); 135.04 (C6); 150.14 (C13); 156.31 (C14); 
162.34 (C8). 
 
3.3 Discussion of Synthetic methods 
3.3.1 Hydroxylated nickel Schiff base complexes  
 
Nickel Schiff base complexes were synthesized according to a general 
literature method.154,155 The hydroxylated Schiff base complexes were first 
synthesized by the reaction of different diamines with either 2,5- or 2,3- 
dihydroxybenzaldehyde in order to form the free Schiff base ligand. 
Subsequent addition of nickel acetate resulted in formation of the 
corresponding nickel complex. The reaction procedure is outlined in Figure 
3.1, with complex (2) as an example. The hydroxylated nickel Schiff base 
complexes were intensely coloured, and insoluble in common organic 
solvents such as methanol, ethanol, and chloroform. They were, however, 





Figure 3.1: Reaction scheme for the synthesis of nickel Schiff base complex 
(2). 
 
The desired nickel Schiff base complexes were obtained as microcrystalline 
powders in good purity and yields (Table 3.1), except for complex (5), which 
was contaminated with an excess of free Schiff base ligand. Therefore, it was 
purified via crystallisation from MeOH/DMSO before being used as the 
starting material for preparing the corresponding alkylated complex. 
The structures of all the synthesized nickel Schiff base complexes were 
confirmed by using MS, 1H NMR and 13C NMR spectral data. Further support 
for the structures of some of the complexes was provided by X-ray 
crystallography, while the purity of the complexes was further assured by 




Table 3.1: Yields of hydroxylated nickel Schiff base complexes. 
Nickel 
complex 
























































Routine 1-dimensional 1H and 13C NMR spectra were not sufficient to fully 
assign the structures of complexes (1)-(6). Therefore, 2D techniques 
including COSY (Correlation Spectroscopy), NOESY (Nuclear Overhauser 
Effect Spectroscopy), HSQC (Heteronuclear Single-Quantum Correlation) 
and HMBC (Heteronuclear Multiple-Bond Correlation) experiments were 
employed. The approach taken to assigning the NMR spectra of the 
hydroxylated nickel Schiff base complexes is discussed below, using 
complexes (2) and (4) as examples. The same process was applied in order 
to assign the NMR spectra of all the other hydroxylated complexes. 
The proton resonances in the 1H NMR spectra were assigned on the basis of 
their chemical shifts, integration, multiplicity and coupling constants. For 
example, the 1H NMR spectrum of the Schiff base complex (2) (Figure 3.2) 
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exhibited three singlets at 8.82, 8.70 and 6.91 ppm which integrate to two 
hydrogen atoms each. As it was expected that the -OH group would give rise 
to a very deshielded singlet, the resonance at 8.82 ppm was tentatively 
assigned to these protons. 
 
 
Figure 3.2: 1H NMR spectrum of complex (2). 
 
In addition, since imine groups are electron withdrawing, their protons are 
also found at relatively high chemical shifts. Therefore, the singlet at 8.70 
ppm was tentatively assigned to the -N=CH protons (H4). The asymmetric 
doublet centred at 6.72 ppm appears to be half of an AB pattern arising from 
coupled protons with similar chemical shifts. The other half of the AB pattern 
is present at 6.91 ppm, but has one of its two resonances obscured by 
overlap with another, larger singlet. The AB pattern is tentatively assigned to 
H8 and H9, while the most likely assignment for the overlapping singlet is H6.  
Evidence for these assignments is provided by the similarity of the chemical 
shifts for H6, H8 and H9 in the spectrum of (2), with that of the corresponding 
hydrogen atoms in the starting material, 2,5-dihydroxybenzaldehyde. Similar 
reasoning led to the conclusion that the two characteristic multiples at 7.29 
and 8.13 ppm should be assigned to H1 and H2, respectively. COSY and 
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NOESY spectra were then obtained to provide support for the above 
assignments as well as complete the identification of resonances to individual 
protons in situations where ambiguity remained, e.g. (H1/H2) and 
(H6/H8/H9). 
COSY NMR spectra contain cross peaks owing to through-bond coupling 
interactions between pairs of protons which are two or three bonds apart. For 
example, the COSY spectrum of complex (2) (Figure 3.3a) shows two strong 
sets of cross-peaks associated with resonances at 7.29 and 8.13 ppm, 
consistent with their assignment to H1 and H2. Additional cross-peaks are 
present for the AB pattern of signals at 6.72 and 6.91 ppm arising from H8 
and H9, as expected. However, COSY is not capable of allowing definitive 
assignment of the individual protons within each of the above pairs of 
resonances. Therefore a NOESY spectrum was acquired to obtain further 






Figure 3.3: a) COSY spectrum of complex (2); b) NOESY spectrum of 
complex (2). Selected key correlations are highlighted. 
 
NOESY is similar to COSY in that it examines the interactions between 
protons in close proximity to each other within the structure of a molecule. 
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However, NOESY identifies pairs of protons that are located close to each 
other through space, even though they may be several bonds apart. The 
NOESY spectrum of complex (2) (Figure 3.3b) shows two strong sets of 
couplings involving the imine proton (H4). The first of these also involves the 
resonance at 8.13 ppm, allowing it to be identified definitively as H2, and the 
signal at 7.29 ppm to H1. The second set of cross peaks involved the 
overlapping set of resonances at 6.90 ppm. This provided support for 
assigning the intense singlet at this chemical shift to H6. Another, weaker 
correlation can be observed between the -OH resonance at 8.82 ppm and 
that at 6.92 ppm. The latter was therefore assigned to H8. Additional cross 
peaks arising from interactions between H1 and H2, as well as H8 and H9, 
are also present in the NOESY spectrum. 
The 13C NMR spectrum of complex (2) (Figure 3.4a) shows ten resonances 
which corresponds to the number of distinct carbon environments expected 
for this complex. Since the 1H NMR spectrum of (2) had now been fully 
assigned, a HSQC spectrum was obtained in an effort to assign each of the 
resonances in the 13C NMR spectrum. The HSQC spectrum in Figure 3.4b 
shows correlations between signals in the 13C NMR spectrum at 115.15, 
116.44, 121.07, 127.25, 127.57 and 155.71 ppm, and individual resonances 
in the proton spectrum. This enabled the corresponding 13C NMR 
resonances to be readily assigned, leaving a further four 13C signals to still 
be attributed to specific carbon atoms. The latter four resonances did not 
show any cross peaks in the HSQC spectrum as they are all due to 
quaternary carbon atoms. These were then assigned based on their chemical 
shifts. Initially the most upfield of these signals at 119.51 ppm was assigned 
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to C5, as it is the only quaternary carbon not directly bound to an O or N 
atom. The signal at 142.81 ppm was then assigned to C3 owing to its 
proximity to the imine group, while the two other signals at 146.78 and 
160.80 ppm were assigned to C7 and C10, respectively. The latter signal is 
the most deshielded of all ten resonances owing to being directly attached to 





Figure 3.4: a) 13C NMR spectrum of complex (2); b) HSQC spectrum of complex 
(2), with C-H correlations highlighted. 
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The NMR spectra of complex (4) were fully assigned using a similar 
approach to that used for (2). The 1H NMR spectrum of this complex is 
shown in Figure 3.5a, together with an expansion of the aromatic region, for 
clarity.  
 
Figure 3.5: a) 1H NMR spectrum of complex (4); b) COSY spectrum of 
complex (4). Key correlations are highlighted. 
 
Based on their characteristic chemical shifts, the upfield singlet at 3.43 ppm 
was assigned to the aliphatic protons H1, whilst the broad singlet at 8.16 ppm 
was assigned to the OH protons. There is also a characteristic downfield 
singlet present at 7.88 ppm, which was assigned to the imine proton (H2). 
The triplet at 6.38 ppm was assigned to H5, as it was expected to show two 
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very similar couplings to H4 and H6. The latter protons gave rise to the two 
doublets of doublets at 6.67 and 6.74 ppm, although at this stage it was not 
possible to definitively assign these multiplets to individual protons. This 
required the use of COSY and NOESY experiments. The COSY spectrum of 
complex (4) (Figure 3.5b) showed, as expected, two strong sets of couplings 
involving H5, one to H4 and the other to H6. This provided further support for 
the assignment of H5 made earlier; however, it still did not allow definitive 
assignment of specific 1H resonances to H4 and H6. A strong coupling was 
observed between the signal at 6.74 ppm, and that assigned to H2 in the 
NOESY spectrum of complex (4) (Figure 3.6). As this coupling was expected 
between H4 and H2 owing to their close proximity through space, the signal 
at 6.74 ppm was then assigned to H4. This in turn now allowed the other 
doublet of doublets at 6.67 ppm to be assigned to H6. 
 




The 13C NMR spectrum of complex (4) (Figure 3.7a) showed the expected 
number of signals for this complex.  
 
Figure 3.7: a) 13C spectrum of complex (4); b) HSQC spectrum of complex 
(4); and c) HMBC spectrum of complex (4), with C-H correlations highlighted. 




Again, a HSQC spectrum (Figure 3.7b) was used to assign those resonances 
arising from carbon signals with at least one directly bound hydrogen atom. 
By using this approach, resonances at 58.45, 114.81, 114.95, 122.40 and 
163.2 ppm could be assigned to specific carbon atoms. The remaining 
carbon resonances at 119.60, 148.15 and 153.13 ppm were all therefore 
deduced to arise from quaternary carbon atoms, which do not show any 
cross-peaks in HSQC spectra. On this occasion, an HMBC spectrum (Figure 
3.7c) was obtained in an effort to assign these signals. HMBC spectra reveal 
correlations between carbon and hydrogen nuclei which are typically 
separated by two or three bonds within a molecule, and may in some 
instances be separated by four or more bonds in conjugated systems.  
The HMBC spectrum in Figure 3.7c shows cross peaks between the 13C 
resonance at 163.21 ppm assigned to C2, and 1H resonances previously 
assigned to H1 and H4. In addition, two sets of artefacts are present in the 
spectrum, one at lower field which is due to the one-bond correlation 
between C2 and H2, and another at higher field, which is due to the one-
bond correlation between C5 and H5. Figure 3.7c also shows two or three 
cross peaks for each of the quaternary carbon signals identified above. Of 
these, the resonance at 119.60 ppm was tentatively assigned to C3 in view of 
its more shielded chemical shift, which is consistent with this carbon atom not 
being directly attached to a highly electronegative atom. Evidence supporting 
this assignment was provided by the two cross peaks in the HMBC spectrum 
involving the resonance at 119.60 ppm, and those from H2 and H5. These 
cross peaks were expected, as C3 is two bonds away from H2, and three 
bonds away from H5. While C8 is also expected to show a strong cross peak 
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with H2, it would not be expected to do so with H5 which is four bonds 
distant. In addition, C8 would be expected to give a less shielded resonance 
owing to its proximity to both Ni and O atoms. Therefore the 13C resonance at 
119.60 ppm was assigned to C3, despite the surprising absence of a cross 
peak with H4 in the HMBC spectrum. The 13C resonance at 153.15 ppm was 
then assigned to C8, primarily on the basis of the observed cross peak with 
H2. In addition, this 13C signal showed cross peaks with resonances from 
both H4 and H6. The remaining quaternary carbon resonance at 148.15 ppm 
was therefore assigned to C7, and as expected showed cross peaks with the 
resonances arising from protons H5 and H6. 
 
3.3.2 Alkylated nickel Schiff base complexes 
 
The nickel Schiff base complexes used for DNA binding studies were 
prepared by reacting the hydroxylated nickel Schiff base compounds with 1-
(2-chloroethyl)piperidine hydrochloride in the presence of K2CO3. This 
reaction was performed using DMF as the solvent, under an inert 
atmosphere of nitrogen gas. Figure 3.8 summarises the conditions used for 





Figure 3.8: Reaction scheme for the synthesis of nickel Schiff base complex 
(8). 
 
The alkylated nickel Schiff base complexes were synthesised according to a 
modified literature method.154 In all cases with the exception of the procedure 
for preparing complex (12), the concentration of the hydroxylated precursor 
complex was 0.03 mM, instead of the 0.01 mM stated in the literature 
method. In addition, although the desired alkylated nickel Schiff base 
complexes precipitated as a coloured solid over the course of reaction, they 
were not isolated immediately by filtration. Instead all of the DMF present in 
the reaction mixture was removed by applying heat under vacuum, and any 
unreacted starting material was subsequently removed by washing with 
water several times. It was found that this isolation procedure improved the 
overall yield of each of the complexes. The yields obtained for each of the 
alkylated complexes synthesised are summarised in Table 3.2. 
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The structure of all alkylated nickel complexes was confirmed using ESI-MS 
as well as a suite of 1D and 2D 1H and 13C NMR spectroscopic techniques. 
The procedure employed to fully assign the 1H and 13C NMR spectra of a 
typical complex is described below, using (8) as an example. 
Figure 3.9 illustrates the full 1H NMR spectrum of complex (8), with 
expansions of the upfield and downfield regions of the spectrum showing the 




Figure 3.9: 1H NMR spectrum of complex (8). 
 
In the aromatic region of the spectrum, two distinctive multiplets are present 
at 7.19 and 7.70 ppm, which strongly resemble signals assigned to H1 and 
H2 in the spectra of related complexes also containing the phenylenediamine 
unit. The COSY spectrum of (8) (Figure 3.10) shows that the above two 
multiplets are coupled to each other, but to no other 1H resonances, 
providing support for the same assignment in the case of the current 
complex. Identification of which of the two resonances should be assigned to 
H1, and which to H2, was then achieved using NOESY spectroscopy. The 
key to this assignment was knowing that the most deshielded 1H resonance 
in the entire spectrum was assigned to the imine hydrogen atom, H4. 
Inspection of the NOESY spectrum (Figure 3.11) shows a clear cross peak 
involving H4 and the resonance at 7.70 ppm, identifying the latter as H2, and 






Figure 3.10:  a) Expanded view of the aromatic region of the COSY 
spectrum of complex (8); b) Expanded view of the aliphatic portion of the 
COSY spectrum of complex (8) selected key correlations are highlighted. 

























































Also apparent in the aromatic region of the 1H NMR spectrum is a set of 
three multiplets shown by the COSY spectrum to be due to a set of three 
coupled protons. The first of these is a doublet at 6.67 ppm with a coupling 
constant of 2.6 Hz, which is indicative of meta proton coupling, as expected 
for H6 owing to the effect of H8 located four bonds away. The remaining 
signals strongly resemble an AB pattern, in which the two upfield resonances 
centred at 7.02 ppm have been further split into doublets with the same 
coupling constant as that found for H6. These upfield signals were therefore 
assigned to H8. The larger coupling for H8 was equal to 9.4 Hz, which is as 
expected identical to that observed for the other two resonances in this AB 
pattern, centred at 7.09 ppm, which were therefore assigned to H9. These 
assignments were supported by the pattern of cross peaks observed for this 
group of three multiplets in the COSY spectrum. 
 




Because of their aliphatic character, the proton signals for the piperidine 
groups all appear in the upfield region of the 1H NMR spectrum. The two 
characteristic triplets at 2.75 and 4.04 ppm integrate to four protons each. 
Therefore, based on their chemical shifts, integration and splitting pattern, 
they were assigned to H12 and H11, respectively. Evidence in support of 
these specific assignments was provided by the NOESY spectrum (Figure 
3.11), which showed a clear cross peak between H6 and the triplet at 4.04 
ppm. This indicates that the latter multiplet must arise from H11, as it is the 
nearer of the two methylene groups to H6. This left three resonances in the 
1H spectrum at 1.50, 1.60 and 2.51 ppm, which required assignment. The 
first of these could be readily assigned to H15, owing to its smaller integration 
compared to that of the two other resonances, as well its chemical shift. The 
multiplet at 1.60 ppm was coupled to each of the other two multiplets arising 
from the piperidine group in the COSY spectrum, allowing it to be assigned to 
H14, and leaving the last broad signal at 2.51 ppm to be assigned to H13. 
This signal was the most deshielded of the 1H resonance arising from the 
piperidine group, owing to the proximity of H13 to an electronegative nitrogen 
atom.  
The 13C NMR spectrum of complex (8) is presented in Figure 3.12a, and 
showed the expected number of signals. An HSQC spectrum was also 
obtained to facilitate assignment of resonances due to carbon atoms with at 
least one hydrogen attached. For example, the 13C signals at 24.35, 26.09 




Figure 3.12: a) 13C NMR spectrum of complex (8); b) HSQC spectrum of 
complex (8); c) HMBC spectrum of complex (8), with C-H correlations 
highlighted. 
 











































































In addition, the two carbon resonances at 127.92 and 127.59 ppm show 
cross peaks with proton resonances which were assigned to H1 and H8, 
respectively, thereby allowing the assignment of the former 13C  signals to C1 
and C8. Some carbon resonances did not exhibit any HSQC cross peaks 
owing to the fact they arise from quaternary carbon atoms, and therefore 
required a HMBC spectrum in order to facilitate their assignment. The HMBC 
spectrum in Figure 3.12c shows two or three cross peaks for each of the four 
carbon resonances identified as arising from quaternary carbon atoms. Of 
these, the most shielded is at 118.56 ppm. This suggests that this resonance 
should be assigned to C5, as it is the only one of the four quaternary carbon 
atoms not directly bonded to an O or N atom. Evidence in support of this 
assignment is provided by the presence of cross peaks in the HMBC 
spectrum involving H4, which is located only two bonds from C5, and H9. 
Perhaps surprisingly, there was no cross peak involving C5 and H6, which 
are also only two bonds distant. The next most shielded quaternary carbon 
resonance is present at 142.89 ppm, and shows cross peaks in the HMBC 
spectrum with the 1H signals arising from H2 and H4. Such cross peaks were 
expected for C3, as it is two bonds away from H2, and three bonds away 
from H4. Therefore the signal at 142.89 ppm was assigned to C3. The two 
remaining quaternary carbon resonances are at 149.18 and 162.80 ppm. The 
first of these showed cross peaks in the HMBC spectrum with H6, H8 and 
H9, while for the second cross peaks involving H4, H6, H8 and H9 were 
observed. These two carbon resonances were assigned to C7 and C10, 
respectively. The observation of a cross peak with H4 was strong evidence in 
favour of assigning the 13C  resonance at 162.80 ppm to C10, as this 
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hydrogen atom is located three bonds away from C10, but is four bonds 
away from C7. Therefore a strong cross peak would not be expected for C7 
and H4. 
The fully assigned 1H NMR spectrum of complex (10) is presented in Figure 
3.13, with expansions of both the aromatic and aliphatic regions also shown 
for clarity. The procedure followed to assign the proton resonances present in 
the aromatic portion of the spectrum was identical to that used for assigning 
signals in the corresponding region of the spectrum of (4) (Section 3.3.1), 
and will therefore not be discussed here. In addition, the assignment of 
resonances in the aliphatic region of the spectrum was accomplished using a 
similar approach to that followed for complex (8), which also contains two 
piperidine groups. 
 
Figure 3.13: 1H NMR spectrum of complex (10). 
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The remaining assignments shown in Figure 3.13 were made with the 
support of information provided by the COSY and NOESY spectra illustrated 
in Figure 3.14 and Figure 3.15, respectively. Both of the latter spectra 
contained cross peaks reflecting the existence of similar coupling patterns to 
those observed in the corresponding spectra of complexes containing similar 
structural moieties to (10). For example, the aromatic region of the 1H and 
COSY NMR spectra of (4) and (10) both contain two doublets and a triplet 
attributable to H4, H5 and H6. 
 
 






Figure 3.15: NOESY spectrum of complex (10). Key correlations are 
highlighted. 
 
Figure 3.16a presents the 13C NMR spectrum of complex (10), which 
contained the expected number of carbon signals. Assignment of the carbon 
signals in the aromatic region of the spectrum was based on a comparison of 
their chemical shifts to those of 13C resonances in the spectrum of complex 
(4), while the carbon signals in the aliphatic portion were assigned after 
comparing their chemical shifts to those of 13C resonances in the spectrum of 
complex (8). These assignments were supported by analysis of the HSQC 
spectrum of (10) shown in Figure 3.16b. For example, the presence of cross 
peaks for 1H resonances assigned to H10 and H1, with the two close carbon 
signals at 57.61 and 58.54 ppm, allowed the latter resonances to be 
assigned to C10 and C1, respectively. The 13C NMR resonance at 124.14 
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ppm was similarly assigned to C4 owing to the presence of a cross peak 
involving H4. By using the remaining HSQC cross-peaks, all the protonated 
carbon resonances were subsequently assigned. 
Long range C-H correlations were used to assign the remaining signals in the 
13C spectrum. The HMBC spectrum in Figure 3.16c shows cross peaks which 
involved the carbon resonance at 120.18 ppm, and those from H2 and H5. 
This enabled the 13C resonance to be assigned to C3, as it is positioned two 
bonds away from H2, and three bonds away from H5. In addition, the 13C 
resonance at 149.95 ppm exhibited cross peaks with resonances from H5, 
H6 and H9. Consequently this 13C resonance was assigned to C7, allowing 
the only remaining unassigned carbon resonance, at 155.83 ppm, to be 
assigned to C8. Consistent with this assignment, the spectrum showed cross 






Figure 3.16: a) The 13C NMR spectrum of complex (10); b) HSQC spectrum 



































































3.4 Crystallographic Data 
 
Single-crystal X-ray diffraction analyses and structure determinations were 
performed by Dr. Anthony Willis, of the Research School of Chemistry, 
Australian National University. Crystals of complex (5) suitable for single-
crystal X-ray analysis were obtained by slow evaporation from a 
methanol/DMSO solvent mixture. Crystals of (8) were obtained by slow 
diffusion of diethyl ether into a solution of (8) in DCM. Crystals of (10) were 
obtained by slow evaporation from a DCM/ petroleum spirit (1:3) solvent 
mixture. ORTEPs showing the solid state structures of these complexes and 
the numbering systems for the non-hydrogen atoms, are presented in Figure 
3.17. Details of collected crystallographic data and structural refinements for 











Table 3.3: Summary of crystallographic data for complexes (5), (8) and (10). 
 (5) (8) (10) 
Formula  (C20H14N2NiO4)3H2O C34H40N4NiO4·H2O C30H40N4NiO4H2O 
M 1233.18 645.44 597.40 
Crystal system Triclinic Triclinic Monoclinic 
Space group P-1 P-1 P21/n 
a (Å) 12.2000(4) 8.1440 (1) 10.1567(3) 
b (Å) 15.0224(5) 11.8552 (2) 8.5596(4) 




74.102(3) 93.0064 (17) - 
β (˚) 71.068 (3) 90.4792 (16) 98.602 (3) 
γ(˚) 69.971(3) 90.5565(15) - 
V (Å3) 2467.88(16) 1504.13 (4) 2858.79(19) 
Dx (Mg m-3) 1.659 1.425 1.388 
Z 2 2 4 
Number of unique reflections 12283 8259 8148 
Refinement R[F2 > 2σ (F2) ] = 0.058 0.030 0.060 




It was observed that the nickel ion in all three crystal structures has adopted 
a square planar coordination geometry. All bond lengths and angles involving 
the central nickel ions (Table 3.4) are consistent with standard values.155,156 
The arrangement of the phenylenediamine moieties in (5) and (8) results in 
N2-C9-C8-N1 torsion angles of 4.21(5)° and -2.42(15)°, respectively. In 
contrast, the arrangement of the ethylenediamine moiety in complex (10) 
results in the same torsion angle increasing to -38.02 (3)°.  
 
Table 3.4: Selected bond lengths (Å) and angles (°) for nickel Schiff base 
complexes. 
Bonds (5) (8) (10) 
Ni-O1 1.847(2) 1.8320 (9) 1.8674(17) 
Ni-O2 1.843(3) 1.8354 (9) 1.8717(19) 
Ni-N1 1.855(3) 1.8557 (11) 1.855(2) 
Ni-N2 1.862(3) 1.8512 (10) 1.855(2) 
O1-Ni-O2 83.82(11) 83.07 (4) 86.49(8) 
O2-Ni-N2 95.12(12) 95.44 (4) 94.17(9) 
O1-Ni-N2 178.25(12) 177.84 (4) 175.35(9) 
O2-Ni-N1 178.58(12) 177.81 (4) 175.42(9) 
O1-Ni-N1 94.76(12) 95.17 (4) 94.55(9) 
N1-Ni-N2 86.29(13) 86.35 (5) 85.16(10) 
 
Complex (5) crystallised in a triclinic crystal system with space group P-1. 
Three molecules of the Schiff base complex called (5A), (5B) and (5C) were 
present, with the central nickel ions labelled Ni1, Ni2 and Ni3, respectively. 
One water molecule was also present in the asymmetric unit. Both oxygen 




bonding interactions with the oxygen atom on the lattice water molecule, with 
the distances for O1-O13 and O2-O13 being 2.83 (6) and 2.91 (6) Å, 
respectively. In addition, both the phenolic and the coordinated oxygen atoms 
of the neighbouring (5B) and (5C) molecules were sufficiently close to one 
another to enable intermolecular O–H···O hydrogen bonds to form, with the 
distances for H11-O6, H12-O6, H7-O9, and H8-O9 being 2.14, 2.09, 2.11 
and 2.10 Å, respectively. 
In the crystal lattice of (5) (Figure 3.18), molecules (5A) and (5B) are 
arranged in a twisted co-facial manner which results in close contacts 
between carbon atoms on the benzylic and phenylenediamine moieties of 
separate nickel molecules. As a result the bond distances for the C6-C31, 
C10-C38, C11-C39, and C18-C26 contacts involving carbon atoms on 
molecules (5A) and (5B) were 3.39, 3.31, 3.34, and 3.35 Å, respectively 
(Figure 3.18a). Molecules (5B) and (5C) assemble in such a way to produce 
short contacts between the benzylic carbons on one molecule, and the 
phenolic oxygens on the adjacent molecule. This results in distances for C36-
O11, C36-O12, C41-O7 and C41-O8 equal to 3.35(5), 3.13(4), 3.27(4) and 
3.38(5) Å, respectively. The most notable contact between (5B) and (5C) 
involved Ni3 and the phenolic oxygen O7, which were located 3.30 Å apart 
(Figure 3.18b). The only contact observed between complexes (5A) and (5C) 
was between the phenolic oxygen atom O11 on complex (5A) and the 
hydrogen atom H71, which is bonded to C7 on complex (5C), at a distance of 







       
 
Figure 3.18: Different perspectives of the stacking of the three nickel 
complexes in the lattice of complex (5): a) all three nickel complexes in the 
crystal lattice; b) the short contacts between complexes (5A) and (5B); c) the 
short contacts between (5B) and (5C). Some hydrogen atoms were omitted 






Complex (8) also crystallised in the triclinic space group P-1, but with one 
metal complex and one water molecule in the asymmetric unit. There were 
hydrogen bonds between the oxygen atoms coordinated to the nickel ion, 
and the oxygen atom on the water molecule, with the distances for H1-O1 
and H1-O2 being 2.21 (3) Å and 2.36 (3) Å, respectively. In contrast, complex 
(10) belongs to the monoclinic crystal system with the space group P21/n. 
One full metal complex and one H2O molecule comprise the asymmetric unit 
of the structure of (10). The oxygen atoms coordinated to the nickel ion and 
the phenolic oxygen atoms are involved in hydrogen bonding interactions 
with the hydrogen atoms of the lattice water molecules, with the distances for 
H1-O1, H1-O3, H2-O2 and H2-O4, being 2.36, 2.36, 2.49, and 2.31 Å, 
respectively.  
In the crystal lattice of (8), the two nickel Schiff base molecules possess a 
crystallographic inversion centre, and they are arranged in a slipped co-facial 
manner (Figure 3.19). The same arrangement has been previously reported 
in the crystal lattice of the complex N,N′-bis-4-(hydroxysalicylidine)meso-
diphenylethylenediaminenickel(II).156 The shortest intermolecular distance 
between the two molecules in the solid state structure of (8) is that between 
the nitrogen atom N1 (coordinated to the nickel ion) and carbon atom C16 on 





Figure 3.19: Perspective view of the stacking of pairs of complexes in the 
lattice of complex (8).  
 
The structure of complex (10) was distinctly bowed around the central 
coordination environment (Figure 3.20). As a consequence the six membered 
chelate rings coordinated to the nickel ion are not completely coplanar with 
each other. This is shown by the angle of 11.01° between the Ni1-O1-C1-C6-
C7-N1 and Ni1-O2-C16-C11-C10-N2 planes. For comparison, the angles 
between the same planes in complexes (5) and (8) were only 0.57° and 






Figure 3.20: View of complex (10) highlighting the non co-planar 
arrangement of the six membered chelate rings around the nickel ion. The 
ethyl piperidine moieties were omitted for clarity. 
 
Two molecules in the unit cell of complex (10) are related by a 
crystallographic inversion centre and assemble in a co-facial manner (Figure 
3.21). The same arrangement was previously reported to be present in the 
solid state structure of the complex (15), and results in the two nickel 
complexes sit neatly on top of one another 156 
This arrangement results in short contacts between the aliphatic carbon atom 
C9 of the ethylenediamine moiety and the two nickel-coordinated oxygen 
atoms O1 and O2 in the adjacent molecule. These pairs of atoms were found 
to be 3.28(3) and 3.27(3) Å, respectively apart. The shortest intermolecular 






Figure 3.21: Perspective view of the stacking of pairs of complexes in the 





CHAPTER 4  
DNA BINDING EXPERIMENTS 
4.1 Introduction  
The ability of the nickel “salphen” complexes, which were prepared via a 
procedure that employed 2,4- dihydroxybenzaldehyde, to bind to the dsDNA 
molecule D2, and the tetramolecular quadruplex Q4, has been investigated 
previously using ESI-MS, CD spectroscopy and UV melting temperature 
measurements.156,157 It was found that the presence of the aromatic system 
in the “top” of the nickel Schiff base complexes may have enabled partial 
insertion of the nickel molecules between the base pairs of the dsDNA. In 
contrast, the extent of binding of nickel Schiff base complexes containing 
either the meso-1,2-diphenylethylenediamine moiety in the “top” of the Schiff 
base to dsDNA was far less extensive. Both classes of nickel molecules 
exhibited significant levels of binding to both tetramolecular and unimolecular 
quadruplex DNA molecules. Examining the effect of changing the length and 
chemical composition of the pendant groups in nickel Schiff base complexes 
on their DNA-binding properties has also been previously explored.155-157 It 
was found that changing the length of the alkyl group connecting the 
piperidine rings to the Schiff base sometimes had a small effect on affinity 
towards either dsDNA or qDNA. Changing the piperidine groups to 
morpholines did not result in any enhancements in DNA affinity or selectivity. 
To date the effect of varying the position of the pendant groups on the Schiff 




selectivity for qDNA over dsDNA, has not been explored. This chapter 
presents the results of ESI-MS and CD spectroscopic studies designed to 
determine whether such structural changes have a significant effect on DNA-
binding properties. 
 
4.2 Results and discussion  
4.2.1 DNA binding experiments performed using nickel 
complexes containing the 1,2-phenylenediamine moiety 
 
Initially, the DNA-binding properties of the three isomeric nickel complexes 
containing a single aromatic ring in the “top” of the Schiff base ligand was 
explored. The structures of these complexes are shown in Figure 4.1. 
Complex (14) has been shown in a number of studies to have significant 





Figure 4.1: Structures of nickel Schiff base complexes containing the 1,2-
phenylenediamine moiety, with ethyl piperidine pendant groups attached at 
different locations on the Schiff base. 
 
In the first instance ESI mass spectra were obtained using solutions 
containing different ratios of the three nickel Schiff base complexes shown in 
Figure 4.1 and the dsDNA molecule D2 (Table 2.1). Figure 4.2 shows the ESI 
mass spectra of a solution containing D2 alone, as well as those containing 
different ratios of D2 and complex (8), which was prepared by a synthetic 





Figure 4.2: Negative ion ESI mass spectra of solutions containing D2 and 
different ratios of (8). (a) Free D2; (b) D2:(8) = 1:1; (c) D2:(8) = 1:3; (d) D2:(8) 
= 1:6; (e) D2:(8) = 1:9.  = free D2;  = [D2 + (8)];  = [D2 + 2(8)];  = [D2 
+ 3(8)];  = [D2 + 4(8)]; = [D2 + 5(8)]; = [D2 + 6(8)]. 
 
The ESI mass spectra of free D2 (Figure 4.2a) contains ions at m/z 1626.5 
and 1952.0, which are attributed to [D2 - 6H]6- and [D2 - 5H]5-, respectively. 
The addition of (8) to D2 led to the appearance of new ions with an overall 
charge of either 6- or 5-, which correspond to non-covalent complexes 
containing one or more intact nickel molecules bound to D2. For example, in 
m/z

































































Figure 4.2b, ions of low abundance with a 6- overall charge appear at m/z 
1731.2, and are attributable to non-covalent complexes containing one nickel 
molecule bound to D2. These may be described as [D2 + (8)]. The same 
non-covalent complex also gave rise to ions with an overall charge of 5- and 
very low abundance at m/z 2077.7. Examination of the spectra in Figure 
4.2a-d shows that the relative abundance of ions from [D2 + (8)] increased as 
the D2:(8) ratio was increased, whilst at the same time the relative 
abundance of ions from free D2 decreased. This trend is consistent with 
more extensive formation of non-covalent complexes as the amount of (8) in 
solution was increased. Further evidence of this is provided by the 
appearance of ions with a 6- charge and very low abundance in Figure 4.2b 
at m/z 1835.8, which are assigned to [D2 + 2(8)]. The relative abundance of 
these ions increased steadily as the ratio of (8) with respect to D2 became 
greater, and they were the ions of greatest abundance in the spectrum of a 
solution containing a D2:(8) with a ratio of 1:9. Concurrently, ions 
corresponding to non-covalent complexes consisting of higher numbers of 
nickel molecules bound to D2 were also seen in medium to high abundance. 
This includes ions with a 6- charge at m/z 1940.4 and 2045.2, which can be 
assigned to [D2 + 3(8)] and [D2 + 4(8)], respectively. Furthermore, the 
spectrum of a solution containing a 1:9 ratio of D2:(8) (Figure 4.2e), showed 
6- ions of very low abundance at m/z 2149.5 and 2253.6, which can be 
assigned to non-covalent complexes consisting of five and six nickel 




In summary, the spectra in Figure 4.2 show that the abundance of ions 
corresponding to non-covalent complexes consisting of increasingly larger 
numbers of nickel molecules bound to D2 grew as the amount of (8) in 
solution was increased. At the same time ions from free D2 diminished in 
abundance as expected. Similar trends were observed for ESI mass spectra 
of solutions containing D2 and the analogous complexes (14) and (11), 
confirming the ability of the latter nickel complexes to also bind to D2. This 
was not a surprising result in the case of complex (14), as its ability to form 
non- covalent complexes with this dsDNA has been previously reported.156 In 
order to compare the binding affinity of complexes (8), (11) and (14) towards 
D2, a series of spectra were obtained of solutions containing the same ratio 
(1:6) of D2 and the nickel complexes. These spectra are shown in Figure 4.3.  
In each spectrum, ions at m/z 1626.5 and 1952.0 are present which are 
attributable to free dsDNA. However, the abundances of these ions vary from 
one spectrum to another, suggesting that the nickel complexes are binding to 
different extents to the DNA. For example, ions at m/z 1626.5 from D2 are of 
lowest abundance in Figure 4.3d, which is a spectrum of a solution 
containing a 1:6 ratio of D2 and (14). This supports the hypothesis that (14) 
has a higher affinity towards D2 than either (8) or (11). Evidence in support of 
this is provided by the observation that the abundance of ions from non-
covalent complexes containing three, four or five nickel complexes bound to 
D2 appears to be slightly greater in the case of the spectrum shown in Figure 
4.3d. Therefore it appears that complex (14), which was prepared via a 




highest affinity of the three isomeric complexes for D2. In this thesis, “affinity” 
is used to describe the overall binding of a nickel complex for a DNA 
molecule based on observation of the amounts of free DNA observed and the 
number of nickel molecules bound. There may, however, be different binding 
modes as more nickel molecules bind, and/or binding of each successive 
nickel molecule may or may not be independent.  
 
 
Figure 4.3: Negative ion ESI mass spectra of solutions containing D2 and 
different nickel Schiff base complexes at a 1:6 ratio. (a) Free D2; (b) D2 + (8); 
m/z




























































(c) D2 + (11); (d) D2 + (14).  = free D2;  = [D2 + (Ni)];  = [D2 + 2(Ni)];  
= [D2 + 3(Ni)];  = [D2 + 4(Ni)]; = [D2 + 5(Ni)]. 
 
The spectra in Figure 4.3b and c also show ions of medium or high 
abundance from non-covalent complexes consisting of two or three nickel 
complexes bound to D2, as well as ions of lower abundance from non-
covalent complexes containing greater numbers of bound nickel molecules. 
Therefore it appears that changing the location of the ethyl piperidine groups 
on the Schiff base complexes had little effect on the ability of (14) to bind to 
and form non-covalent complexes with D2. 
Inspection of Figure 4.3 suggests that the order of binding affinity of these 
three nickel complexes for D2 is: (14) > (8) > (11). However, in order to 
confirm this conclusion, it was necessary to calculate and compare the 
relative abundances of ions from free D2 and different types of non-covalent 
complexes seen in all three spectra. Therefore the relative abundances were 
calculated by adding the individual abundances of all ions assigned to free 
DNA or a specific non-covalent complex in a given spectrum, and dividing the 
result by the sum of the abundances of all ions present in that spectrum. 
Figure 4.4 shows how the relative abundances of ions varied from the 
spectrum of one solution to another. The figure shows that complex (14) 
binds the most extensively to D2, as the relative abundances of ions from 
non-covalent complexes consisting of two, three or four molecules of (14) 
bound to D2 are greater than for the corresponding ions containing either of 






Figure 4.4: Relative abundances of ions in spectra of solutions containing D2 
and different nickel Schiff base complexes at a 1:6 ratio. 
 
In addition, Figure 4.4 also shows that the relative abundances of ions from 
non-covalent complexes consisting of one or four molecules of (8) or (11) 
bound to DNA is essentially identical. However, the relative abundances of 
ions from non-covalent complexes containing two molecules of (8) bound to 
D2 is greater than that for the corresponding non-covalent complexes 
containing (11). This observation, along with a lower relative abundance of 
ions from D2, suggests that the affinity of (8) is slightly greater than that of 
(11). Therefore the results illustrated in Figure 4.4 support the order of 
binding affinity proposed earlier for these three complexes: (14) > (8) > (11). 
Overall the extent of non-covalent complex formation with D2 did not vary 
greatly between the three nickel complexes, suggesting that the position of 
the ethyl piperidine moiety does not have a major impact on affinity towards 

































hypothesis further, CD spectra were obtained of solutions containing different 
ratios of the three nickel Schiff base complexes and D2, and are presented in 
Figure 4.5. 
Circular dichroism (CD) spectroscopy is routinely used along with other 
techniques such as FTIR difference spectroscopy, ESI-MS and UV-visible 
absorption spectrophotometry, to study conformational changes of DNA.165-
168 The CD signal of normal (B-form) DNA arises from the asymmetric carbon 
atoms present in the sugar residues, and its helical structure. Changes to the 
CD spectrum of DNA may be brought about as a result of conformational 
changes resulting from the binding of different compounds, or a change in 
the surrounding solution conditions. Depending on the mode or extent of 
binding of a small molecule, DNA can either remain in its original structure, or 
may transform into another secondary structure such as A-form or Z-form 
DNA. Each of these secondary structures gives rise to a distinct spectrum 
featuring CD bands at different wavelengths.166,169,170 In addition, it is 
possible to provide evidence in support of the binding modes used by small 
molecules to bind to DNA, such as intercalation, groove binding and 
electrostatic interaction, by monitoring the changes in intensity and position 
of CD bands.171-174 Therefore, CD spectroscopy is considered to be one of 
the most powerful techniques for providing information about the nature of 
interactions between metal complexes and dsDNA. 
The CD spectra presented in Figure 4.5 show the effect of addition of 
increasing amounts of each of the three nickel complexes upon the CD 




large positive and negative CD bands centred at 282 nm and 249 nm, 
respectively. These values are characteristic for B-form DNA.166 The addition 
of the metal complexes to the DNA resulted in changes to the ellipticity and 
positions of the CD bands, which are summarised in Table 4.1. 
 
Figure 4.5: Circular dichroism spectra (200-400 nm) of solutions containing 
D2 and different ratios of nickel Schiff base complexes. (a) D2 + (8); (b) D2 + 
(11); (c) D2 + (14). 
 
Table 4.1: Effect of addition of nickel Schiff base complexes on the CD 
spectrum of D2.*  
Nickel 
complex 
Positive CD band at 282 nm 
Δλ (nm)          Δɛ (mdeg) 
Negative CD band at 249 nm 
Δλ (nm)             Δɛ (mdeg) 
(8) 1.9 -1.5 -2.6 2.2 
(11) 0.7 -1.5 1.5 0.4 
(14) -2.0 -1.9 -0.5 4.0 
* All Δλ and Δε values are the difference between the values for free DNA 
and those for a solution containing a DNA:nickel complex ratio of 1:9. 
Negative Δλ values indicate a blue shift; positive values indicate a red shift. 


























































containing no metal complex, and εmax for the same CD band for the solution 
with the highest DNA:nickel complex ratio. 
Inspection of Figure 4.5c suggests that overall the addition of (14) to D2 
caused the largest changes to the CD spectrum of D2, whereas the addition 
of (11) resulted in the smallest changes (Figure 4.5b). These conclusions are 
reinforced by the results presented in Table 4.1. The most notable effect 
caused by addition of a nickel complex was the change in ellipticity of the 
negative CD band upon addition of (14). Addition of 9 equivalents of this 
nickel complex more than doubled the initial ellipticity of this CD signal. 
Furthermore, the change in ellipticity caused by addition of (14) was almost 
double that observed upon addition of the same amount of (8), and 10 times 
larger than that seen with complex (11). Addition of (14) also resulted in a 
slightly larger change to the ellipticity of the positive CD band than that 
caused by either (8) or (11). It is also worthwhile noting that addition of (14) 
resulted in a small blue shift for the positive CD band of D2, whereas the 
other two nickel complexes had the opposite effect, possibly indicating subtle 
differences in their modes of interaction. Inspection of Table 4.1 shows that 
the magnitude of changes to the position and ellipticity of both CD bands 
generally increased in the order: (14) > (8) > (11), which is the same as the 
order of increasing binding affinities derived from the ESI-MS studies 
presented earlier. 
In order to investigate the binding of (8), (11) and (14) to tetramolecular 
quadruplex DNA, a similar series of ESI-MS and CD experiments to those 
described above, was also performed with Q4 (Table 2.1). Figure 4.6 shows 




(14). The spectrum of a solution containing Q4 alone (Figure 4.6a), contains 
ions of low and high abundance at m/z 1675.1 and 2010.4, which are 
assigned to [Q4 + 4NH4+ - 10H]6- and [Q4 + 4NH4+ - 9H]5-, respectively. The 
presence of four ammonium ions in these ions in not surprising, and provides 
support for the conclusion that the tetramolecular quadruplex structure 
initially formed in solution has been successfully transferred to the gas 
phase. This is because Q4 contains five G-tetrads, and would therefore be 
expected to trap four unimolecular cations in between each quartet. Since the 
mass spectra were obtained using solutions of Q4 in ammonium acetate, it is 
not surprising that those four unimolecular cations were all ammonium ions. 
 
 
Figure 4.6: Negative ion ESI mass spectra of solutions containing Q4 and 
different nickel Schiff base complexes at a 1:6 ratio. (a) Free Q4; (b) Q4 + 
m/z
























































(8); (c) Q4 + (11); (d) Q4 + (14).  = free Q4;  = [Q4 + (Ni)];  = [Q4 + 
2(Ni)];  = [Q4 + 3(Ni)];  = [Q4 + 4(Ni)]; = [Q4 + 5(Ni)]. 
After addition of the nickel Schiff base complexes, none of the spectra 
showed ions from free DNA. This observation suggests that each of the three 
complexes has a significant affinity towards Q4, and is in contrast with what 
was observed for D2 (Figure 4.3). Further examination of Figure 4.6b-d 
reinforces this view. For example, each of the spectra in Figure 4.6b and d 
contain ions of high abundance at m/z 2261.7, which correspond to [Q4 + 
2(Ni) + 4NH4+ - 13H]5-, which may be more simply stated as  [Q4 + 2(Ni)]. In 
addition, ions of low to medium abundance are present at m/z 2387.3, which 
are attributable to [Q4 + 3(Ni)]. These observations confirm that each of the 
isomeric nickel complexes exhibits a significant and similar degree of affinity 
towards Q4. In order to determine the order of binding affinities towards this 
qDNA molecule, the relative abundances of each of the ions observed was 
calculated, and is presented in Figure 4.7. Inspection of the figure shows that 
the only nickel complex to form non-covalent complexes with Q4 that 
involved five bound nickel molecules was (11). This observation, combined 
with the slightly higher abundances of ions from [Q4 + 3(11)] and [Q4 + 
4(11)], compared to the corresponding ions containing either (8) or (14), 
suggests that (11) may have the highest overall affinity of the nickel 
complexes for this tetramolecular quadruplex. Examination of Figure 4.7 also 
reveals that while the relative abundances of ions from [Q4 + 2(Ni)] is greater 
for (14) than for (8), the converse is true in the case of ions arising from [Q4 
+ 3(Ni)]. This suggests that (8) and (14) have very similar affinities for Q4, 




(11) > (8) ≈ (14). This order is essentially the reverse of what was obtained 
from studies involving the dsDNA molecule D2. It therefore appears that the 
nature and extent of binding modes used by the nickel complexes with the G-
quadruplex DNA molecule may be slightly different to those used in 
interactions with dsDNA.  
 
 
Figure 4.7: Relative abundances of ions in ESI mass spectra of solutions 
containing Q4 and different nickel Schiff base complexes at a 1:6 ratio. 
 
Comparison of Figure 4.4 and Figure 4.7 shows that the abundances of ions 
from free D2 in the spectra of solutions containing a nickel complex and this 
DNA molecule were between 4 and 22 %, while ions from free Q4 were 
absent in the spectra of solutions containing a nickel complex and this 
tetramolecular G-quadruplex. This indicates that while complexes (8), (11) 
































cases with Q4. It is also worth reflecting on the observation that although 6 
equivalents of nickel complexes were added to the solutions used to obtain 
the spectra shown in Figure 4.6, the most abundant ions in each case were 
from non-covalent complexes consisting of just two nickel molecules bound 
to the quadruplex. It therefore appears that after two nickel molecules are 
bound to Q4, further binding events occur less readily. This may be because 
the preferred binding sites for the nickel molecules are the two G-quartets at 
either end of the quadruplex. Once these sites become occupied, further 
binding interactions with lower affinity sites in this relatively small qDNA 
molecule are inhibited because of steric hindrance and electronic factors.  
Circular dichroism spectroscopy was then used to provide support for or 
against the above order of nickel binding affinities towards Q4, determined 
using ESI-MS. Circular dichroism spectroscopy has also been used 
previously to characterise the different topologies of quadruplex DNA, and 
monitor changes in its conformation upon interaction with different DNA-
binding ligands.166,175-178 Each qDNA conformation gives a characteristic CD 
spectrum.166,175,178,179 For example, a parallel G-quadruplex displays a 
positive CD band at 260 nm, whereas an anti-parallel G-quadruplex displays 
a negative CD band at this wavelength. In addition both types of quadruplex 
DNA conformations give an additional positive CD band around 210 nm. The 
CD spectra illustrated in Figure 4.8 show the effect of adding increasing 
amounts of each of the three nickel complexes on the CD spectrum of Q4. 




and negative CD peaks centred at 264 nm and 243 nm, respectively, which 
are characteristic for parallel DNA quadruplexes.166  
Inspection of Figure 4.8 shows that the addition of (8) or (14) to Q4 caused 
larger changes to the ellipticity of the positive CD band, compared to that 
which resulted from the addition of (11). Table 4.2 summarises the changes 




Figure 4.8: Circular dichroism spectra (200-400 nm) of solutions containing 
Q4 and different ratios of nickel Schiff base complexes. (a) Q4 + (8); (b) Q4 + 
(11); (c) Q4 + (14).  

































































Table 4.2: Effect of addition of nickel Schiff base complexes on the CD 
spectrum of Q4.* 
Nickel 
complex 
Positive CD band at 264 nm Negative CD band at 243 nm 
Δλ (nm) Δɛ (mdeg) Δλ (nm) Δɛ (mdeg) 
(8) -0.5 -17.6 -0.9 6.1 
(11) 2.9 -8.1 -1.7 2.3 
(14) -0.8 -21.0 -1.4 6.9 
* All Δλ and Δε values are the difference between the values for free DNA 
and those for a solution containing a DNA: nickel complex ratio of 1:9. 
Negative Δλ values indicate a blue shift; positive values indicate a red shift. 
Δε values are the difference between εmax for this CD band for the solution 
containing no metal complex, and εmax for the same CD band for the solution 
with the highest DNA:  nickel complex ratio. 
 
Inspection of Table 4.2 shows that addition of 9 equivalents of (14) and (8) 
decreased the ellipticity of the positive CD band by 21.0 and 17.6 mdeg, 
respectively. In contrast, the change resulting from the addition of (11) was 
only 8.1 mdeg. Although this smaller change in ellipticity is consistent with 
the notion that (11) has a lower affinity towards Q4 than either of the other 
nickel complexes, its addition did result in a red shift to the position of this CD 
band that was greater than the blue shifts caused by (8) or (14). This 
highlights the sensitivity of CD spectroscopy to subtle changes in DNA 
conformation caused by the addition of isomeric complexes such as those 
investigated in this thesis. The larger changes to the ellipticity of the positive 
CD band caused by addition of (8) and (14) were mirrored by proportionately 
larger changes also to the ellipticity of the negative CD signal. If it is assumed 
that changes in ellipticity are more indicative of the overall strength of the 
metal/DNA binding interactions than alterations to the positions of the CD 
signals, then the order of binding affinity for the three complexes is: (14) > (8) 




ESI-MS experiments, with the positions of complexes (11) and (14) being 
reversed. If instead the shift in position of the more intense, positive CD band 
is used as a measure of the binding ability of the nickel complexes, then the 
overall order of binding affinity is: (11) > (14) ≈ (8). This sequence is 
essentially the same as that derived from the ESI-MS study, suggesting that 
changes in position of the positive CD band, although they may be typically 
small in magnitude, may more accurately reflect the extent of metal/DNA 
interactions.  
The significant difference in binding affinity series based on changes to the 
ellipticity of the positive CD band, and the extent of non-covalent complex 
formation revealed in the ESI-MS study, is perhaps not surprising as the 
methods exhibit varying sensitivities to different aspects of the binding 
interaction. In the case of ESI-MS, the results reflect stability of non-covalent 
complexes in the gas phase, whilst the changes to the CD spectrum are the 
result of changes to DNA conformation in the solution. In the absence of 
qualitative or quantitative binding data obtained by applying other techniques, 
it is therefore impossible to know whether ESI-MS or CD spectroscopy 
provides the best overall picture of the relative DNA-binding affinity of a 
group of related metal complexes. 
 
4.2.2 DNA binding experiments performed using nickel 
complexes containing the 1,2-ethylenediamine moiety 
 
This section explores the effect of changing the position of the appended 




affinity of the resulting nickel complexes ((7) and (10)) towards D2 and Q4. 
The structures of these three complexes are shown in Figure 4.9. 
 
 
Figure 4.9: Structures of nickel Schiff base complexes containing the 1,2-
ethylenediamine moiety, whose binding to dsDNA and qDNA are explored in 
this section. 
 
The binding affinity of complex (13) has been examined previously,155,157 and 
was found to exhibit a lower binding affinity towards both of the above DNA 
molecules than the corresponding salphen complex (14). This was attributed 
to the former complex having one less aromatic ring able to contribute to 




alternatively interact with a terminal G-quartet of Q4. It was hoped that 
altering the points of attachment of the ethyl piperidine groups might facilitate 
additional favourable binding interactions that compensate for these issues, 
and thereby endow complexes (7) and (10) with superior DNA affinity and/or 
selectivity to the complexes discussed in the previous section.  
A series of ESI-MS experiments was performed using solutions containing a 
1:6 ratio of each of the three nickel complexes and the dsDNA molecule D2. 
Figure 4.10 shows the ESI mass spectra of these solutions. The relative 
abundances of all the ions observed were then calculated and are presented 
in Figure 4.11. Each of the spectra in Figure 4.10b-d shows ions at m/z 
1626.2 and 1952.5, which correspond to [D2 - 6H]6- and [D2 - 5H]5-, 
respectively. These ions are present in medium to high abundance in Figure 
4.10c, and with low to medium abundance in Figure 4.10b and d. This 
suggests that the binding affinity of these nickel complexes toward D2 is 
generally less than that of nickel complexes with the 1,2-phenylenediamine 
moiety at the “top” of the molecule, namely (8), (11) and (14). This is because 
the relative abundances of ions from free D2 in ESI-mass spectra of solutions 







Figure 4.10: Negative ion ESI mass spectra of solutions containing D2 and 
different nickel Schiff base complexes at a 1:6 ratio. (a) Free D2; (b) D2 + (7); 
(c) D2 + (10); (d) D2 + (13).  = free D2;  = [D2 + (Ni)];  = [D2 + 2(Ni)];  
= [D2 + 3(Ni)];  = [D2 + 4(Ni)]. 
 
Inspection of Figure 4.10 shows that the abundances of ions from free DNA 
followed the order: (13) < (7) < (10). This suggests that the order of relative 
DNA binding affinities is the opposite sequence; namely (10) < (7) < (13). 
Further evidence for the conclusion that (13) has the highest affinity towards 
D2 of these complexes is provided by Figure 4.11, which shows that the 
relative abundances of ions from [D2 + 2(Ni)] were highest for this nickel 
complex. Furthermore, (13) was the only nickel complex to give rise to ions of 
m/z
























































significant abundance from non-covalent complexes containing three bound 
nickel molecules.  
 
 
Figure 4.11: Relative abundances of ions from free DNA and different non-
covalent complexes in spectra of solutions containing D2 and different nickel 
Schiff base complexes at a 1:6 ratio. 
 
Examination of Figure 4.11 also provides evidence that (10) has the lowest 
affinity towards D2 of the three nickel complexes. Foremost amongst this is 
the observation that the relative abundance of ions from free D2 is greater 
than that of any of the non-covalent complexes present, only in the case of 
the spectrum obtained from the solution containing (10). In addition, the 
relative abundances of ions from [D2 + (10)] and [D2 + 2(10)] were both 
significantly less than that for the corresponding ions arising from non-
covalent complexes containing (7). Confirmation of the lower affinity of 
complex (10) towards D2, compared to that exhibited by (13), is also 

































ions from [D2 + 2(10)] is much lower than that of ions from [D2 + 2(13)]. 
Furthermore, the absence of ions from non-covalent complexes of the type 
[D2 + 3(10)] also supports this conclusion. 
The results presented in Figure 4.10 and Figure 4.11 show that binding 
affinity towards D2 was not enhanced by changing the position of the ethyl 
piperidine groups from those they occupy in complex (13). This is the same 
conclusion as that reached previously for complexes containing the 
phenylenediamine moiety in the top region of the Schiff base ligand, 
suggesting that the 4-position may be generally the optimal location for these 
substituents.  
In order to provide further support for the above conclusions, CD spectra 
were obtained of solutions containing different ratios of (7), (10) or (13), and 
D2, and are presented in Figure 4.12. Inspection of Figure 4.12b and c 
shows that the addition of either (10) or (13) to D2 caused no significant 
changes to the CD spectrum of D2. These observations suggest that (10) 
and (13) do not interact to a notable extent with this dsDNA molecule. This 
conclusion contrasts markedly with that based on the results of the ESI-MS 
study presented earlier, which suggests that (13) had the greatest ability of 
the three nickel complexes to form non-covalent complexes with dsDNA. This 
apparent dichotomy in the results may be a reflection of the two experimental 
techniques used being more sensitive to different aspects of the metal 
complex/DNA interaction, as outlined earlier in this chapter, and commented 
on by others. For example, Davis et al. found that CD experiments 




complexes, to those indicated by ESI-MS studies.156 These researchers 
reported that mass spectral studies suggested that nickel salphen complex 
(14) binds to D2 to a significant extent, however, the addition of this complex 
to D2 caused no significant changes to the CD spectrum of the nucleic acid. 
This may be because electrostatic interactions are well-maintained in the gas 
phase relative to hydrophobic interactions, and binding modes in which one 
type of interaction predominates over others may result in a bias in ESI-MS 
experiments.180 CD spectra show only bulk effects and give no information 
about the different complexes that may be present in a mixture.  
 
 
Figure 4.12: Circular dichroism spectra (200-400 nm) of solutions containing 
D2 and different ratios of nickel Schiff base complexes. (a) D2 + (7); (b) D2 + 


























































Figure 4.12a shows that addition of complex (7) had the greatest effect on 
the ellipticity of three major CD bands. For example, addition of 9 equivalents 
of (7) increased the ellipticity of the negative CD band by 3.3 mdeg. The 
contrast been the effect of addition of complex (7) on the CD spectrum of D2, 
and that caused by addition of either (10) or (13), is summarised by Table 
4.3, which presents the changes in wavelength and ellipticity of the two 
principal CD bands caused by addition of the three nickel complexes. 
 
Table 4.3: Effect of addition of nickel Schiff base complexes on the CD 
spectrum of D2.* 
Nickel 
complex 
Positive CD band at 282 nm Negative CD band at 252 nm 
Δλ (nm) Δɛ (mdeg) Δλ (nm) Δɛ (mdeg) 
(7) -2.8 -1.4 -2.6 3.3 
(10) 1.1 -0.8 2.2 -1.2 
(13) -0.6 -0.7 2.1 1.2 
* All Δλ and Δε values are the difference between the values for free DNA 
and those for a solution containing a DNA:nickel complex ratio of 1:9. 
Negative Δλ values indicate a blue shift; positive values indicate a red shift. 
Δε values are the difference between εmax for this CD band for the solution 
containing no metal complex, and εmax for the same CD band for the solution 
with the highest DNA:nickel complex ratio. 
 
The variation in the magnitude of the changes in ellipticity of the CD bands at 
252 and 282 nm suggests the following binding affinity order: (7) > (13) ≈ 
(10). The difference between this binding affinity sequence, and that derived 
by ESI-MS, can be explained by proposing that the location of the ethyl 
piperidine moieties in complex (7) enables it to participate in slightly different 
modes of DNA binding to that employed by (13) and (10). Furthermore, the 




conformation and therefore the CD spectrum, but does not afford non-
covalent complexes sufficient stability to withstand the environment of the 
mass spectrometer. Despite the apparent differences in binding affinity order 
that the two techniques suggest for complexes (7) and (13), both methods 
give results consistent with the conclusion that complex (10) has the lowest 
affinity towards D2 of the three nickel complexes. 
A series of ESI-MS experiments was also performed using solutions 
containing a 1:6 ratio of the tetramolecular quadruplex Q4, and either (7), 
(10) or (13). These experiments were performed to provide the information 
required to make an assessment of whether altering the position of the ethyl 
piperidine groups favourably affects the selectivity of the nickel complexes for 
qDNA over dsDNA. Figure 4.13 shows the mass spectra obtained of the 





Figure 4.13: Negative ion ESI mass spectra of solutions containing Q4 and 
different nickel Schiff base complexes at a 1:6 ratio. (a) Free Q4; (b) Q4 + 
(7); (c) Q4 + (10); (d) Q4 + (13).  = free Q4;  = [Q4 + (Ni)];  = [Q4 + 
2(Ni)];  = [Q4 + 3(Ni)];  = [Q4 + 4(Ni)]. 
 
After addition of the nickel Schiff base complexes, the only spectrum to show 
ions from free DNA was that presented in Figure 4.13c, which was of a 
solution containing a 1:6 ratio of Q4 and (10). This observation, combined 
with the much lower abundance of ions from non-covalent complexes 
consisting of [Q4 + 2(10)], compared to that of analogous ions in the spectra 
shown in Figure 4.13b and d, indicates that (10) has the lowest affinity of 
these three nickel complexes for this particular tetramolecular quadruplex. 
Reinforcing this conclusion is the observation that the most abundant ions in 
m/z




















































Figure 4.13c are from [Q4 + (10)]. In contrast, the most abundant ions in 
Figure 4.13b and d are from [Q4 + 2(7)] and [Q4 + 2(13)], respectively. 
Furthermore, Figure 4.13b and d both show ions of low to medium 
abundance at m/z 2358.1, from [Q4 + 3(Ni)], which are of greater abundance 
than the corresponding ions in the spectrum of the solution containing (10). 
Comparison of Figure 4.13b and d does not, however, enable a 
determination as to which of complexes (7) and (13) has the highest affinity 
towards Q4 to be readily made. Therefore in order to address this question 
the relative abundances of each of the ions present in Figure 4.13b-d were 
calculated, and are presented in Figure 4.14.  
 
Figure 4.14: Relative abundances of ions in ESI mass spectra of solutions 


































Examination of Figure 4.14 shows that while the abundance of ions from [Q4 
+ (Ni)] is perhaps slightly greater for (7) than (13), the opposite was true for 
ions arising from non-covalent complexes of the type [Q4 + 3(Ni)]. These 
observations, together with the very similar relative abundances of ions from 
[Q4 + 2 (Ni)], for complex (7) and (13), suggests that the affinity of these two 
nickel complexes towards Q4 are very similar. The preference of Q4 to bind 
two molecules of (7) and (13) is striking, and was also evident in Figure 4.6 
based on the results presented in Figure 4.14, the overall order of binding 
affinity for these three complexes is: (13) ≈ (7) > (10). This is very similar to 
the order of DNA affinities obtained for these nickel complexes from ESI-MS 
binding studies involving the dsDNA molecule D2. 
It is possible to gain insight into the DNA-binding selectivity of the three nickel 
complexes by comparing the relative abundance data present in Figure 4.11 
and Figure 4.14. This reveals that the most abundant non-covalent 
complexes present in the spectra of solutions containing a 1:6 ratio of either 
D2 or Q4, and (10) are from [D2 + (10)] and [Q4 + (10)], respectively. This 
suggests that the binding affinity of (10) towards Q4 and D2 is quite similar. 
In contrast, complexes (7) and (13) appear to have a preference for binding 
to Q4 over D2, as the relative abundances of ions attributable to non-
covalent complexes containing one or more molecules of (7) or (13) bound to 
Q4 are higher than for the analogous non-covalent complexes involving D2. 
This indicates that both (7) and (13) display a degree of binding selectivity in 
favour of Q4, which is greater than that exhibited by (10). Furthermore, the 




indicate that moving the ethyl piperidine groups from their locations in 
complex (13), to their positions in (7) did not improve selectivity towards Q4.  
In order to further explore the effects of changing the location of the ethyl 
piperidine groups on DNA selectivity, CD spectra were obtained of solutions 
containing different ratios of Q4 and either (7), (10) or (13). These spectra 
are presented in Figure 4.15, while the changes in position and ellipticity of 
the CD bands are compiled in Table 4.4. 
 
 
Figure 4.15: Circular dichroism spectra (200-400 nm) of solutions containing 
Q4 and different ratios of nickel Schiff base complexes. (a) Q4 + (7); (b) Q4 + 
(10); (c) Q4 + (13). 
 


































































Table 4.4: Effect of addition of nickel Schiff base complexes on the CD 
spectrum of Q4.* 
Nickel 
complex 
Positive CD band at 264 nm Negative CD band at 243 nm 
Δλ (nm) Δɛ (mdeg) Δλ (nm) Δɛ (mdeg) 
(7) -1.2 -9.2 -0.4 3.0 
(10) 0.9 -1.7 -0.8 0.0 
(13) -0.1 -1.6 -0.3 1.3 
* All Δλ and Δε values are the difference between the values for free DNA 
and those for a solution containing a DNA:nickel complex ratio of 1:9. 
Negative Δλ values indicate a blue shift; positive values indicate a red shift. 
Δε values are the difference between εmax for this CD band for the solution 
containing no metal complex, and εmax for the same CD band for the solution 
with the highest DNA:nickel complex ratio. 
 
Inspection of the results shows that the addition of either (10) or (13) to Q4 
had essentially no effect on the CD spectrum of the DNA. The absence of 
notable changes to the CD spectrum is perhaps not too surprising in the case 
of complex (10), as it showed the poorest ability to form non-covalent 
complexes with this quadruplex molecule in ESI-MS experiments. In contrast, 
complex (13) was shown to exhibit the highest affinity towards Q4, thereby 
making the absence of any effect it has on the CD spectrum of this 
quadruplex another example of a surprising result that can best be explained 
by reflecting on the differing abilities of the two analytical methods to 
differentiate complexes employing different binding modes. 
Figure 4.15a shows that the effect of addition of (7) on the CD spectrum of 
Q4 is greater than that elicited by the other two complexes. Most notably, the 
ellipticity of the positive CD band decreased by 9.2 mdeg, which was by far 
the largest change observed. Complex (7) also had the largest effect on the 
CD spectrum of D2 (Figure 4.12). This suggests that complex (7) is able to 




used by other nickel complexes, and which results in the largest changes to 
the conformation of these DNA molecules. 
 
4.2.3 DNA binding experiments performed using nickel 
complexes containing the meso-1,2-diphenylethylene-
diamine moiety 
 
Previous work showed that nickel complex (15), containing the meso-1,2-
diphenylethylenediamine moiety, exhibited a significant degree of DNA 
selectivity as a consequence of exhibiting a comparable ability to most other 
complexes of this type to bind to Q4, but essentially no ability to interact with 
D2.156 It was therefore decided to synthesise complex (12), in which the two 
ethyl piperidine groups are located in different positions to those they occupy 
in (15), to see if this complex might retain the ability to bind to dsDNA 
conferred by the diamine moiety in the “top” of the Schiff base ligand, but 
more avidly bind to Q4. This section compares the DNA-binding properties of 
(12) and (15), whose structures are shown in Figure 4.16. It was initially 
hoped to also be able to extend this investigation to the third isomer, complex 
(9). However, the latter complex could not be obtained in sufficient purity to 





Figure 4.16: Structures of nickel Schiff base complexes containing the meso-
1,2-diphenylethylenediamine moiety, whose binding to dsDNA and qDNA are 
explored in this section. 
 
Initially ESI mass spectra were obtained of solutions containing a 1:6 ratio of 
D2 and the two different nickel complexes (Figure 4.17). Both spectra 
showed ions with high abundance at m/z 1626.6 from [D2 - 6H]6-, as well as 
ions of low to medium abundance at 1952.0 from [D2 - 5H]5-. In fact the 
spectra in Figure 4.17b and c are very similar to each other, and to the 
spectrum of the solution containing only D2, which is shown in Figure 4.17a. 
These observations support the view that neither (12) or (15) have significant 
affinity towards D2. This view is reinforced by the observation of ions of only 
low to very low abundance which can be attributed to the formation of non-
covalent complexes between the nickel molecules and D2, and is consistent 
with the results of a published investigation into the affinity of complex (15) 






Figure 4.17: Negative ion ESI mass spectra of solutions containing D2 and 
different nickel Schiff base complexes at a 1:6 ratio. (a) Free D2; (b) D2 + 
(12); (c) D2 + (15).  = free D2;  = [D2 + (Ni)];  = [D2 + 2(Ni)]. 
 
The results of the present study therefore both confirm the results of the 
previous study which showed that (15) exhibits very low affinity towards 
D2,156 and also suggests that changing the position of the ethyl piperidine 
groups on the Schiff base ligand has little impact on the ability to bind to this 
type of nucleic acid molecule. Instead the results reaffirm the view that the 
presence of the non-planar meso-1,2-diphenylethylenediamine moiety 
prohibits strong interactions with D2, perhaps by hindering the approach of 
these molecule to the dsDNA to bind via partial intercalation or groove 
binding.  
In order to provide further evidence that changing the position of the ethyl 
piperidine groups in (15) does not significantly affect affinity of the nickel 
molecule towards D2, CD spectra were obtained of solutions containing 
m/z









































different ratios of D2 and either (12) or (15). Figure 4.18 shows the CD 
spectra obtained of these solutions, while Table 4.5 present the changes in 
position and ellipticity of the individual CD bands of the nucleic acid caused 
by addition of 9 equivalents of the nickel complexes.  
 
Figure 4.18: Circular dichroism spectra (200-400 nm) of solutions containing 
D2 and different ratios of nickel Schiff base complexes. (a) D2 + (12); (b) D2 
+ (15). 
 
Table 4.5: Effect of addition of nickel Schiff base complexes on the CD 
spectrum of D2.* 
Nickel 
complex 
Positive CD band at 282 nm Negative CD band at 252 nm 
Δλ (nm) Δɛ (mdeg) Δλ (nm) Δɛ (mdeg) 
(12) 0.7 -1.2 0.6 0.9 
(15) 1.4 -3.2 2.4 3.9 
* All Δλ and Δε values are the difference between the values for free DNA 
and those for a solution containing a DNA:nickel complex ratio of 1:9. 
Negative Δλ values indicate a blue shift; positive values indicate a red shift. 
Δε values are the difference between εmax for this CD band for the solution 
containing no metal complex, and εmax for the same CD band for the solution 
with the highest DNA:nickel complex ratio. 
 
Addition of complex (12) had only a minor effect on the CD spectrum of D2, 
as expected, since this complex showed little ability to bind to D2 in the ESI-







































MS experiments. In contrast, the addition of (15) did have a significant effect 
on both major CD bands of the nucleic acid. This was a surprising result, as 
(15) also showed a very poor ability to form non-covalent complexes in the 
solutions used to obtain ESI mass spectra. The observation that complex 
(15) did cause significant changes to the CD spectrum of D2, whereas 
addition of (12) did not, again highlights the high degree of sensitivity of CD 
spectroscopy to what are perhaps small differences in how different metal 
complexes affect the conformation of nucleic acids. It is worthwhile noting 
that the change in ellipticity of the positive band of D2 caused by addition of 
(15) was greater than that caused by addition of any of the other nickel 
complexes investigated in this study. For example, the decrease in ellipticity 
of the positive CD band of D2 caused by addition of (15) (3.2 mdeg) was 
almost double that observed upon addition of the same amount of either (7), 
(8), (11) or (14). Addition of (15) also resulted in a larger change to the 
ellipticity of the negative CD band of D2 than that caused by any of the other 
nickel complexes investigated in this thesis, with the exception of complex 
(14), which resulted in an equivalent change. 
The results in the previous section indicate that changing the location of the 
ethyl piperidine groups from where they are situated in complex (15), to their 
positions in (12), did not change the very low affinity exhibited by the former 
complex towards a typical dsDNA molecule. This meant that if this change in 
structure resulted in an increase in affinity towards Q4, compared to that 
exhibited by (15), then complex (12) could be considered to display a greater 




To investigate this possibility, ESI mass spectra were obtained of solutions 
containing Q4 and either (12) or (15) at a DNA:nickel complex ratio of 1:6. 
The spectrum of the solution containing Q4 and (12) (Figure 4.19b), shows 
ions from free DNA with low and medium abundance at m/z 1675.4 and 
2010.7, respectively. These ions do not, however, appear in the spectrum of 
the solution containing Q4 and (15). This observation, combined with the 
lower abundance of ions from [Q4 + 2(Ni)] in Figure 4.19b, compared to that 
of analogous ions in Figure 4.19c, indicates that (12) has a slightly lower 
affinity towards Q4 than (15).  
 
 
Figure 4.19: Negative ion ESI mass spectra of solutions containing Q4 and 
different nickel Schiff base complexes at a 1:6 ratio. (a) Free Q4; (b) Q4 + 















































The results presented in Figure 4.17 and Figure 4.19 therefore suggest that 
changing the location of the ethyl piperidine groups, from where they are in 
complex (12), to where they are in (15), did have a small, but favourable 
effect on selectivity for Q4. In order to test this conclusion, CD spectra were 
obtained of solutions containing different ratios of either (12) or (15) and Q4, 
and are presented in Figure 4.20. Table 4.6 summarises the changes to the 
position and ellipticity of both CD bands caused by addition of the two nickel 
complexes. 
 
Figure 4.20: Circular dichroism spectra (200-400 nm) of solutions containing 
different ratios of Q4 and nickel Schiff base complexes. (a) Q4 + (12); (b) Q4 
+ (15). 
 
Table 4.6: Effect of addition of nickel Schiff base complexes on the CD 
spectrum of Q4.* 
Nickel 
complex 
Positive CD band at 264 nm Negative CD band at 243 nm 
Δλ (nm) Δɛ (mdeg) Δλ (nm) Δɛ (mdeg) 
(12) 1.5 -11.8 -1.2 5.1 
(15) -1.0 -4.8 -0.7 4.1 
* All Δλ and Δε values are the difference between the values for free DNA 
and those for a solution containing a DNA:nickel complex ratio of 1:9. 
Negative Δλ values indicate a blue shift; positive values indicate a red shift. 
Δε values are the difference between εmax for this CD band for the solution 
containing no metal complex, and εmax for the same CD band for the solution 
with the highest DNA:nickel complex ratio. 














































Figure 4.20 reveals that the addition of increasing amounts of either (12) or 
(15) to a solution of Q4 resulted in small changes to the CD spectrum of the 
nucleic acid. Surprisingly, it was found that the changes to the position of the 
CD bands caused by addition of (12) were greater than that caused by 
addition of (15) (Table 4.6). This suggests that (12) may exhibit a higher 
binding affinity than (15) toward Q4, which contrasts with the conclusion 
reached on the basis of the results obtained from the ESI-MS study. Most 
notable was the significant decrease in ellipticity of the positive CD band of 
11.8 mdeg caused by addition of 9 equivalents of (12) (Table 4.6). In 
contrast, addition of (15) only changed the ellipticity of this CD band by 4.8 
mdeg. This therefore represents one final example where the results 
obtained from DNA-binding studies performed using the two different 
instrumental methods must be interpreted with caution, as they most likely 






CHAPTER 5 CONCLUSIONS 
The ability of nickel Schiff base complexes to bind selectively to quadruplex 
DNA has attracted significant attention in recent years. This is a 
consequence of their ease of synthesis, and the combination of structural 
and electronic properties that endow upon them the ability to bind effectively 
to these nucleic acid secondary structures. Previous investigations in this 
area have focussed on the DNA-binding interactions of complexes such as 
(13), (14) and (15), which were prepared via a two-step procedure that 
involved initially the reaction between different diamines and 2,4-
dihydroxybenzaldehyde, in the presence of nickel(II).156,157 Subsequently the 
hydroxyl groups present in the resulting compounds were derivatised using 
1-(2-chloroethyl) piperidine hydrochloride to afford nickel complexes with 
sufficient water solubility for studying their DNA-binding behaviour in aqueous 
solution. It was shown that changing the diamine used in the initial step of the 
synthetic procedure can have a significant effect on affinity towards either or 
both dsDNA and qDNA.156 
One aspect of the structure of the above complexes, whose effect on DNA-
binding properties had not been examined previously, was the location of the 
ethyl piperidine moieties on the Schiff base ligand. The current investigation 
into the effect of such alterations was prompted by both the absence of 
information concerning the effects of such changes, and the knowledge that 
the ethyl piperidine groups have been shown to play a significant role in 




this thesis was to use a combination of two different techniques, ESI-MS and 
CD spectroscopy, to investigate the effects of varying the position of the ethyl 
piperidine groups in the nickel Schiff base complexes, on their abilities to 
bind to a duplex 16mer DNA molecule and a tetramolecular DNA quadruplex. 
Over the course of this project five novel alkylated nickel Schiff base 
complexes were prepared, which featured ethyl piperidine moieties in 
different locations to those in previously studied compounds. All new 
compounds were synthesised in high purity, and characterised using NMR 
spectroscopy, ESI-MS and microanalysis. In addition, the solid-state 
structures of two of these nickel complexes, as well as one of the precursor 
complexes, were determined by single crystal X-ray diffraction methods. 
ESI-MS and CD spectroscopy were both used to assess the extent of binding 
interactions between the nickel complexes and DNA. In the case of ESI-MS, 
it was assumed that the abundance of ions from non-covalent complexes 
containing different numbers of nickel molecules bound to DNA would reflect 
the extent of the binding interactions, and could be used to determine relative 
orders of binding affinity. Addition of the nickel complexes in some instances 
produced changes to the position and, in particular the ellipticity, of the 
principal features in the CD spectra of D2 and Q4. The magnitudes of these 
changes were also used to determine relative orders of binding affinity, that 
were then compared to those determined from ESI mass spectra. 
On some occasions both the ESI-MS and CD spectroscopic results gave 
essentially the same conclusions regarding the impact of changing the 




example, variations in the relative abundances of ions from non-covalent 
complexes observed in ESI mass spectra, and changes to the ellipticity of the 
positive CD band of D2, both suggested that the affinity of complex (14) for 
this DNA molecule was at least as great as, if not greater than, that of the two 
isomeric molecules (8) and (11). Addition of (14) did produce a small blue 
shift for this CD signal, in contrast to the red shifts observed upon addition of 
the other two nickel complexes, perhaps suggesting some subtle differences 
in their modes of DNA binding. Overall, however, it appeared that changing 
the position of the ethyl piperidine groups from their positions in the 
previously studied complex (14) had only a small effect on affinity towards 
the dsDNA molecule D2.  
The results of ESI-MS studies into the binding of the other two series of 
nickel complexes to D2 also suggested that changing the position of the ethyl 
piperidine moieties from where they are located in the two lead complexes, 
((13) and (15)) did not enhance affinity towards this dsDNA molecule. For the 
complexes prepared using ethylenediamine as one of the starting materials, 
the relative abundances of ions from non-covalent complexes containing one 
or more molecules of (13) bound to D2 was greater than that for analogous 
ions containing either (7) or (10). This suggests that changing the location of 
the ethyl piperidine moieties from their location in (13) was in fact detrimental 
to the ability of the complex to bind to dsDNA. A different conclusion was 
reached upon analysis of the changes observed to the CD spectrum of D2 
when (7), (10) or (13) was added, as it was the former nickel complex which 




both prepared via synthetic routes involving meso-1,2- 
diphenylethylenediamine as one of the starting materials, exhibited 
essentially no ability to form non-covalent complexes with D2 in ESI mass 
spectral experiments. This suggests that neither complex exhibits a 
significant ability to bind to dsDNA. Surprisingly, however, addition of (15) 
resulted in the biggest changes to the CD spectrum of D2 of any of the nickel 
complexes examined.  
In order to develop an understanding of the origin of variations in binding 
affinities derived by the two techniques, such as those discussed above, it is 
important to reflect upon differences between the two instrumental 
techniques used. In the case of mass spectrometry, the spectra obtained 
show ions from non-covalent complexes which have sufficient stability to 
pass from the solution to the gas phase. It has been proposed that 
electrostatic interactions may play an important role in maintaining non-
covalent complexes during the ESI process and in the gas phase, and 
therefore be a contributing factor to the differences with the DNA-binding 
results obtained via the two methods.180 Essentially, two different non-
covalent complexes with the same stability as reflected in an overall binding 
constant, may exhibit different relative abundances of ions in ESI mass 
spectra, if the contributions of electrostatic interactions to their overall stability 
vary. In contrast, CD spectroscopy is uniquely sensitive to the effects that 
binding of small molecules can have on the chirality of DNA molecules. 
Therefore even a relatively minor component of the overall binding interaction 




spectrum of the latter, or another type of DNA molecule, if the interaction 
alters the helicity of the nucleic acid. It is not a requirement for such binding 
interactions to survive on being transferred from solution to the gas phase, in 
order for its effects to become apparent in a CD spectrum. 
Differences between orders of binding affinity determined on the basis of 
ESI-MS and CD experiments were even more prevalent amongst studies 
conducted using the tetramolecular quadruplex Q4. The results of binding 
studies performed using mass spectrometry suggested that for two of the 
three series of complexes studied it was the lead nickel complex, prepared 
using a synthetic pathway that employed 2,4-dihydroxybenzadehyde, which 
exhibited the highest binding affinity. For the complexes containing an 
ethylenediamine moiety, complex (13) showed a greater ability to form non-
covalent complexes with Q4 than either (7) or (10), while for those featuring 
the 1,2-meso-diphenylethylenediamine moiety in the “top” of the molecule, 
complex (15) proved to have a higher affinity than (12). The results of the 
binding experiments performed using CD spectroscopy yielded a different 
perspective for both series of complexes. Complex (7), prepared via a 
pathway that involved 2,5-dihydroxybenzaldehyde, had a bigger impact on 
the CD spectrum of Q4 than either (10) or (13), mimicking the results 
obtained in binding studies involving D2. Addition of (15) to a solution of Q4 
did not affect the CD spectrum of the latter as much as the introduction of 
(12), which was prepared using 2,3-dihydroxybenzaldehyde as one of the 
initial reactants. This result is in direct contrast to what was expected on the 




containing the phenylenediamine moiety in the “top” of the Schiff base ligand 
also produced different results in ESI-MS and CD experiments involving Q4. 
On this occasion, the results of the CD investigation showed that the isomer 
prepared using 2,4-dihydroxybenzaldehyde, complex (14), had the biggest 
impact, thereby suggesting it may have the greatest binding affinity. In 
contrast, the results of the ESI-MS study performed using this series of three 
nickel complexes indicated that (11) was more capable of forming non-
covalent complexes with Q4, than either (8) or (14). The results of ESI-MS 
experiments performed using this triad of nickel complexes, and both types of 
DNA molecules, suggest that (11) may have a greater degree of binding 
selectivity in favour of Q4 over D2, than either of the other complexes. 
However, the changes observed to the CD spectra of Q4, in particular, cast 
doubt over this assessment. It should be noted that where binding is 
predominantly stabilised by hydrophobic interactions, such as end-stacking 
on a tetramolecular qDNA, it is thought that such interactions are either 
unchanged in strength or weakened relative to electrostatic interactions.180 
End-stacking has been observed for the binding of the anthracycline, 
daunomycin, to a molecule similar to Q4.115 
The results of the ESI-MS investigations carried out as part of this study 
suggest that, in general, changing the location of the ethyl piperidine moieties 
on the Schiff base ligand did not have a great effect on affinity for either type 
of DNA molecule. Most of the new nickel complexes, with the exception of 
(12), showed a significant ability to form non-covalent complexes with D2 and 




mass spectra of solutions containing this nickel complex and D2 were almost 
completely devoid of ions arising from non-covalent complexes formed 
between the metal complex and dsDNA molecule. This was not unexpected 
as complex (15), which also features the 1,2-meso-diphenylethylenediamine 
moiety in the “top” of the Schiff base ligand, was shown previously by a 
variety of methods to have a very low affinity towards dsDNA molecules.156 
Incorporation of this structural unit into the Schiff base ligand therefore 
appears to consistently have a far more significant impact upon DNA binding, 
at least in the case of the dsDNA molecule D2, than changing the location of 
the ethyl piperidine moieties. 
In some instances the magnitude of changes to the CD spectrum of D2 and 
Q4 were generally consistent with what would be predicted using DNA 
affinities based on ESI-MS studies of the same systems. However, on many 
occasions there were significant discrepancies between DNA binding 
affinities based on relative ion abundances on the one hand, and the 
magnitude of changes to the ellipticity of CD signals arising from DNA, on the 
other. It should be noted that addition of nickel complexes resulted in 
changes to both the position and ellipticity of the CD signals arising from D2 
and Q4. However, the magnitude of the red and blue shifts of the CD bands 
was always very small, suggesting that the strength of the overall binding 
interactions may not be that great, and that this parameter is unlikely to be an 
accurate measure of subtle changes in binding affinities. In contrast, on some 




observed, including where the results of ESI-MS investigations into the same 
system did not suggest a strong overall binding interaction.  
The above observations highlight that care must be taken when interpreting 
in isolation the results of DNA-binding studies performed using different 
techniques. ESI-MS and CD spectroscopy may be uniquely suited to 
providing information about different aspects of the metal complex/DNA 
interaction. CD spectroscopy can probe subtle changes in binding mode but 
offers a view of only bulk solution effects. ESI-MS allows for high-throughput 
screening, and is suitable for small sample sizes and allows observation of all 
species present in the sample. Under some conditions, the disadvantage of 
ESI-MS may be in comparing the abundances of complexes where the 
relative contributions of hydrophobic versus electrostatic interactions are 
vastly different, and one type predominates to a great extent over the other. 
The fact that different techniques for observing snapshots of equilibria have 
different advantages and disadvantages is not surprising.  
It is therefore recommended that other spectroscopic techniques commonly 
applied to examining metal complex/DNA interactions be used to explore the 
systems presented in this thesis. Absorption spectrophotometry, which can 
be used to provide a measure of the overall strength of binding interactions in 
the form of a binding constant, and fluorescence resonance energy transfer 
(FRET) spectroscopy, which affords this information in the form of changes to 
the melting temperature of a DNA molecule, are two such methods widely 
used by the bio-inorganic chemistry community for this purpose. It would be 




affinity that match more closely those derived here using ESI-MS or CD 
spectroscopy. If this were to prove to be the case, it would not necessarily 
follow that the other technique should be abandoned for examining these 
binding interactions. In contrast, it may allow a stronger focus to be turned to 
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